The role of EBV-encoded microRNAs in B cell differentiation by Ross, Nathan Arlen
THE ROLE OF EBV-ENCODED 
MICRORNAS IN B CELL 
DIFFERENTIATION 
Nathan Ross 
B.App.Sc. (Hons) 
 
 
Submitted in fulfilment of the requirements for the degree of 
Master of Applied Science (Research) 
 
School of Biomedical Sciences 
Faculty of Health 
Queensland University of Technology 
Submitted December 2012 
 
  
 i 
The Role of EBV-Encoded MicroRNAs in B Cell Differentiation i 
 
Keywords 
BART11-5p 
B cell differentiation 
Bim 
Early B cell factor (EBF1) 
Epstein-Barr virus (EBV) 
Methyl CpG binding protein 2 (MECP2) 
microRNA (miRNA) 
luciferase silencing assays. 
ii 
ii The Role of EBV-Encoded MicroRNAs in B Cell Differentiation 
Abstract 
Epstein Barr virus (EBV) is a common γ-herpes virus, infecting approximately 
90% of the world‟s population. It is also one of the first known viruses known to be 
oncogenic, and is associated with a number of tumour types, primarily lymphomas. 
MicroRNAs (miRNAs) are post-transcriptional regulators of gene expression and 
many human miRNAs have been associated with the development of malignancies 
including cancer. EBV was the first human virus identified to express miRNAs and 
encodes more than 40 miRNAs within its genome. Yet, an understanding of the 
targets of EBV-miRNAs, and thereby the function of them in pathogenesis remains 
sadly limited. 
This study identifies a potential novel target of EBV-miRNAs, MECP2 and 
characterises the miRNA:mRNA interactions between two previously identified 
novel targets; Bim and EBF1. In particular, this study  focuses upon the interaction 
between EBF1 and the EBV-miRNA BART11-5p, demonstrating a 151bp region of 
the EBF1 3‟UTR that is capable of mediating the silencing of luciferase expression 
by BART11-5p but is not capable of silencing a full length EBF1-3‟UTR luciferase 
construct. This study provides evidence that EBF1 may be a target of one or more 
EBV-miRNAs. 
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Chapter 1: Introduction 
1.1 INTRODUCTION 
Epstein Barr virus (EBV) is a particularly successful and prolific gamma herpes 
virus, infecting greater than 90% of the population (Young & Rickinson, 2004). EBV 
preferentially infects naïve B lymphocytes. Through a series of viral gene expression 
programs, known as latency programs, the virus evades immune surveillance and drives 
infected cells through a B cell terminal differentiation process (Thorley-Lawson & Gross, 
2004). This gives the virus access to the long lived memory B cell compartment allowing 
persistence for the life of the host. 
Although EBV infection normally results in a benign state, EBV is also associated 
with a number of B cell lymphomas; including Burkitt lymphoma (BL), Hodgkin lymphoma 
(HL), diffuse large B cell lymphoma (DLBCL) and post-transplant lymphoproliferative 
disease (PTLD) (Gandhi et al., 2004; Nguyen-Van et al., 2011; Nourse et al., 2011). As such, 
it is important to understand the role of EBV in these malignancies to facilitate development 
of more specific and effective treatments. 
EBV has demonstrated the capacity in vitro to transform naïve B cells into a 
lymphoblastoid cell line (LCL). This process is regulated by the expression of EBV latency 
genes, several of which act as constitutively active homologues of B cell differentiation. 
However, the relationship of EBV latency gene expression to lymphoma is not fully 
understood (Khanna et al., 2005).  
In addition to the well-characterised latency genes, EBV also expresses a large 
number of viral microRNAs (miRNAs). miRNAs are small RNA molecules (usually 20-22 
nucleotides in length) that attenuate gene expression at a post-transcriptional level (Nourse et 
al., 2012; Skalsky et al., 2012; Winter et al., 2009). They are important developmental 
regulators and have been associated in the development of many cancers. Research into the 
role and function of the miRNAs expressed by EBV is still limited and comparatively few 
targets of these miRNAs have been identified, both in the EBV and human genomes. 
However, studies have determined EBV-miRNAs play a role primarily in protecting infected 
cells from apoptosis and immune evasion (Ramalingam et al., 2012). 
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In unpublished preceding work (Ross et al., 2009) we have identified three novel 
potential targets of EBV-miRNAs; Bim, EBF1 and HLA-DOA and this forms the foundation 
of this study. 
1.2 AIMS AND SIGNIFICANCE OF THE STUDY 
Relatively few targets of EBV-miRNAs within the human genome have been 
identified and fully verified and as such their role in EBV pathogenesis and 
lymphomagenesis is not well understood. We hypothesise that EBV-miRNAs target human 
genes via distinct sites within their 3‟UTRs and that these target genes play roles in 
apoptosis, the immune response and B cell differentiation. This study builds upon our 
previous work (Ross et al., 2009) (Appendix 2) with further elucidation and validation of the 
potential targets identified. In particular, this study will focus upon the BART miRNA 
BART11-5p due to the findings of our previous work. Further, BART11-5p has been 
demonstrated to be highly expressed in normally infected cells, suggesting its potential role 
in pathogenesis. Confirmation of these targets provides a greater understanding of the 
function of EBV-miRNAs. 
The goals of this study were set as four specific aims. 
1. Validate the previous findings in an improved luciferase reporter system 
addressing limitations of the system used previously. 
2. Identify and experimentally verify the specific EBV-miRNA target sites 
within the candidate genes. 
3. Identify and experimentally verify the specific miRNAs responsible for the 
repression of the candidate targets. 
4. Expand the pool of potential targets using bioinformatic predictions and 
validated using the improved luciferase reporter system. 
1.3 REVIEW OF THE LITERATURE 
In order to understand the context of this study, it must be placed within the context of 
the previous research. This includes an understanding of normal B cell development as well 
as lymphoma and a thorough understanding of EBV biology. The function of miRNAs in 
humans and other model systems has been well-characterised although much is still 
unknown, particularly in regards to the parameters governing binding and silencing of 
targets. Research of human miRNAs informs much of the growing research into viral 
miRNAs. 
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1.3.1 B CELL DIFFERENTIATION IN GERMINAL CENTRES 
B cell differentiation is a complex, multifaceted process that involves fine control 
over both the survival and growth mechanisms within differentiating cells. The terminal 
differentiation of mature naive B cells within the lymph node begins when the B cell 
receptor (BCR) binds its cognate antigen. This signal alone is not sufficient to initiate B cell 
differentiation; cells also require additional signals from T helper cells, primarily via CD40 
on the naive B cell (Laman et al., 1996). 
Activated B cells within lymph nodes begin the differentiation process by migrating 
into lymphoid follicles and undergoing rapid proliferation, forming the germinal centre 
microenvironment (Natkunam, 2007). The germinal centre is divided into the light and dark 
zones. These zones are associated with the two stages of the germinal centre reaction, 
proliferation and selection and cells progress between these two zones (MacLennan, 1994). 
Within the dark zone, the differentiating B cells, at this stage termed centroblasts, undergo 
rapid proliferation while the IgV or variable region of the BCR undergoes somatic 
hypermutation (SHM), generating a wide array of BCRs with different affinities for the 
cognate antigen. 
Within the light zone proliferation is slowed and selection of cells possessing a high 
affinity BCR occurs. At this stage, the differentiating B cells are now termed centrocytes. At 
odds to the proliferative behaviour of germinal centre B cells within the dark zone, the 
apoptotic signalling pathways within these cells are tightly controlled, rendering germinal 
centre B cells extremely sensitive to apoptotic stimuli (Fischer et al., 2007; Natkunam, 
2007). Centrocytes possessing low affinity receptors or crippling mutations are quickly 
removed by Fas or BCR-mediated apoptosis (Takahashi et al., 2001). Survival signals 
originate from other cells within the light zone; follicular dendritic cells (FDCs) present 
cognate antigen to differentiating B cells and T helper cells provide survival signals both 
through CD40 and by secretion of cytokines (Allen et al., 2007b). Class switching also 
occurs at this stage of differentiation, a proportion of the differentiating centrocytes will 
switch to expression of IgA, IgE and IgG receptors (Natkunam, 2007). Mature B cells 
emerge from the germinal centre as memory B cells, secreting high affinity antibodies as part 
of the adaptive immune response or recognising antigens in subsequent infections 
respectively. 
While differentiating B cells have traditionally been thought to progress through the 
germinal centre reaction in a linear fashion, from naïve cells, to centroblasts, to centrocytes 
and finally terminally differentiated memory cells; more recent studies indicate that the 
germinal centre reaction is a much more complex process than previously thought. B cells 
4 
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undergoing the germinal centre reaction are highly motile within the germinal centre, 
moving back and forth between the light and dark zones to undergo several rounds of 
proliferation and selection before exiting the germinal centre as mature B cells (Allen et al., 
2007a; Schwickert et al., 2007). Neither is proliferation and apoptosis mutually exclusive to 
either zone. 
1.3.2  EBV TRANSFORMATION OF B CELLS 
As described above EBV infects B lymphocytes and establishes lifelong persistence 
in peripheral memory B cells in a latent immunosilent state. While EBV has been 
demonstrated to infect B cells at all stages of differentiation in vitro and transform them into 
LCLs, the aetiology of in vivo infection is more contentious. One theory holds that EBV 
preferentially infects naïve B cells and drives them through an atypical germinal centre 
reaction (Thorley-Lawson, 2001). This model suggests that upon initial infection, the full 
complement of EBV latency genes is expressed, termed the latency III program and that as 
differentiation progresses, the latency gene expression profile is increasingly restricted 
(Joseph et al., 2000). This is supported by in vitro studies which demonstrate that infection 
of naive B cells alters the expression of B cell differentiation genes into a more germinal 
centre-like phenotype (Roughan & Thorley-Lawson, 2009; Thorley-Lawson & Mann, 1985). 
However, an alternate theory proposes that memory B cells are infected directly (Chaganti et 
al., 2009).  
The mechanisms of EBV-induced transformation of B cells are not fully understood 
but are primarily controlled by a suite of EBV latent proteins which are expressed in distinct 
latency programs that are associated with the differentiation status of the infected cell. Many 
latent proteins affect the infected cell by altering the expression of key B cell proteins and 
acting as constitutively active homologues of key cell surface receptors. Latent membrane 
proteins 1 and 2A (LMP1 and LMP2A) are key B cell transforming proteins, LMP1 and 
LMP2A are constitutively active homologues of CD40 and the BCR respectively, enabling 
infected cells to differentiate in the absence of antigen and T helper cell stimulation 
(Caldwell et al., 1998; Kilger et al., 1998). Further, LMP2A inhibits the signalling activity of 
the BCR; BCR signalling can induce apoptosis in memory B cells (Guerreiro-Cacais et al., 
2010). The EBV nuclear antigens (EBNAs) are important transcription factors that control 
the expression of both viral and cellular genes. The EBNA proteins play an important role in 
regulating the expression of a number of proliferative and apoptotic genes. EBNA2 activates 
c-Myc, which promotes proliferation but also sensitises infected cells to apoptosis (Kaiser et 
al., 1999). EBNA3A and EBNA3C repress the expression of the proapoptotic gene Bim, 
which plays a critical role in enhancing the resistance of infected cells to apoptosis 
(Anderton et al., 2008; Paschos et al., 2009).  
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1.3.3 EBV ASSOCIATED MALIGNANCIES 
The presence of EBV has been noted in several B cell lymphomas and appears to be 
associated with these malignancies to varying degrees. 
1.3.3.1 BURKITT LYMPHOMA 
There are two main subtypes of BL; endemic BL is found primarily in equatorial 
Africa while sporadic BL is prevalent in the Western world. In endemic regions of equatorial 
Africa EBV is believed to act in concert with malaria to induce the formation of BL with the 
association between EBV and BL in these areas is almost 100% (Rickinson & Kieff, 2001). 
In contrast, the association of EBV with non-endemic (sporadic) BL is 20-30% (Rickinson & 
Kieff, 2001). The expression of viral genes in BL is limited and expresses only the  latency I 
program which consists of EBNA1, which is responsible for controlling the replication of the 
viral episome and the non-coding RNAs EBERs and BART genes (Rowe et al., 1986). 
1.3.3.2 HODGKIN LYMPHOMA 
The association of EBV with Hodgkin‟s lymphoma in regions of Latin America is 
also almost 100% but in the Western world the association is ~40%(Jarrett & MacKenzie, 
1999). Hodgkin‟s lymphomas are believed to originate from germinal centre B cells that 
have acquired crippling mutations during SHM and managed to evade apoptosis though the 
B cell phenotype has been lost in Hodgkin‟s lymphoma (Kanzler et al., 1996). EBV infected 
Hodgkin‟s lymphomas the latency II phenotype, expressing EBNA1 but in addition express 
both LMP1 and 2A (Deacon et al., 1993). 
1.3.3.3 POST TRANSPLANT LYMPHOPROLIFERATIVE DISORDER 
PTLDs are nearly always EBV positive and the immunosuppressive treatment is 
believed to be a major factor in enhancing the risk of PTLD (Capello et al., 2005; Knowles, 
1998). PTLDs are also believed to have a germinal centre origin, with some tumours 
showing crippling mutations from SHM were observed (Chadburn et al., 1998). PTLDs 
usually express all of the latent EBV genes although more restricted phenotypes have been 
observed (Knowles, 1998). 
1.3.4 STRUCTURE AND FUNCTION OF MICRORNAS 
miRNAs are small, single-stranded RNA molecules which negatively attenuate gene 
expression (Lau et al., 2001). This is achieved by a number of mechanisms, including 
mRNA degradation, deadenylation and, most commonly in humans, translational repression 
(Winter et al., 2009). miRNAs are involved in numerous physiological and pathological 
processes, including development, differentiation and cancer (Zhang et al., 2009). 
6 
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miRNAs broadly follow a common biogenesis pathway which is regulated by 
several factors to control the expression of mature miRNAs (Figure 1). miRNAs are encoded 
within the genome as primary miRNAs (pri-miRNAs). Pri-miRNAs consist of a terminal 
loop and a hairpin stem which contains the mature miRNA with flanking regions on either 
side of the stem. Pri-miRNAs are principally transcribed by RNA polymerase II but may also 
be transcribed by RNA polymerase III (Borchert et al., 2006; Lee et al., 2004). Pri-miRNA 
transcripts are subsequently processed by the microprocessor complex containing the 
endonuclease Drosha and DGCR8 to release an approximately 70 nucleotide short hairpin 
stem with a terminal loop termed a precursor miRNA (pre-miRNA), (Han et al., 2004; Lee et 
al., 2003). Pre-miRNAs are then exported to the cytoplasm by exportin 5 (Hutvagner et al., 
2001; Yi et al., 2003).  Here processing by a second nuclease, Dicer, removes the terminal 
loop and produces an approximately 22 nucleotide miRNA duplex consisting of the mature 
miRNA guide strand and a passenger strand (Hutvagner et al., 2001; Yi et al., 2003). This 
miRNA duplex is then incorporated into the RNA-induced silencing complex (RISC) where 
the guide strand is selected based on the stability of the base pairing at the 5‟ end, with the 
less stable being selected as the guide strand and loaded onto RISC (Khvorova et al., 2003). 
Once part of RISC, the mature miRNA acts as the targeting component, binding the 
nucleotide sequence of targeted mRNAs and resulting in gene silencing (Winter et al., 2009). 
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Figure 1. The current model for the biogenesis and post-transcriptional suppression 
of microRNAs and small interfering RNAs. Figure is sourced from (He & Hannon, 2004). 
 
The identification of genes targeted by miRNAs is a particularly difficult challenge 
as the target sites, which are normally located within the mRNA 3‟untranslated region 
(UTR), bind the miRNA with imperfect complementarity. While several binding 
characteristics of miRNAs to target sites have been identified, the precise criterion for 
recognition of target sites is still unknown. The imperfect complementarity of binding 
between miRNAs and their target sites generates RNA secondary structures, which are 
believed to play a major role in targeting miRNAs to target sites. In addition secondary 
structure is thought to influence the mechanism by which target genes are repressed. In 
general, targets bound with a high degree of complementarity are cleaved and degraded via 
similar mechanisms used by siRNAs whilst targets bound with lower complementarity have 
translation repressed.  A number of bioinformatic algorithms have been developed to 
predict miRNA targets though these algorithms generate a large number of false positive 
results (Chaudhuri & Chatterjee, 2007; Grimson et al., 2007; John et al., 2004; Lewis et al., 
2005). Recent studies have also demonstrated the development of a number of chromatin 
8 
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immunoprecipitation assays which can directly examine the interactions of RISC with target 
sites and potentially provide and experimental way of screening genomes for miRNA targets 
rather than relying on bioinformatic methods (Dolken et al., 2010; Marin et al., 2012; 
Skalsky et al., 2012). 
1.3.5 MICRORNAS AND LYMPHOMA 
The regulation of miRNA expression is crucial in many developmental pathways, 
including B cell differentiation. As such, the dysregulation and over expression of certain 
miRNAs has been associated with the development of many disease states including 
lymphoma.  
Among the most common lymphoma, DLBCL, the miRNA expression profile can 
vary widely and contributes to the diagnosis of different subtypes (Malumbres et al., 2009; 
Wright et al., 2003). One of the miRNAs aberrantly expressed in DLBCL is miR-155 and 
this miRNA is among the best characterised, not only in DLBCL but many other cancers. 
miR-155 is a crucial regulator of the germinal centre response and attenuates several 
important processes during the germinal centre reaction including somatic hypermutation 
(SHM) and class switch recombination (CSR). It does so by regulating many crucial genes 
including AID, CD10 and PU.1 (Teng et al., 2008; Thai et al., 2007; Thompson et al., 2011; 
Vigorito et al., 2007). miR-155 expression can be used to distinguish between two DLBCL 
subtypes; activated B cell-like (ABC) and germinal centre B cell-like (GCB) (Eis et al., 
2005; Lawrie et al., 2009). Further, several miRNAs have been identified that can be used to 
predict prognosis and severity of DLBCL (Alencar et al., 2011; Malumbres et al., 2009). 
In contrast to DLBCL, the expression of miR-155 is absent in Burkitt lymphoma and 
its absence may be related to other markers of Burkitt lymphoma such as Myc translocation 
and CD10 expression (Di Lisio et al., 2012; Dorsett et al., 2008; Kluiver et al., 2006). 
Translocation of the c-Myc gene is one of the hallmarks of Burkitt lymphoma. c-Myc 
regulates the expression of a number of miRNAs including miR-17-92, miR-34b and several 
of the let-7 miRNA (Bueno et al., 2011; Mu et al., 2009). Some of these in turn target c-Myc, 
generating a complex autoregulatory loop and contribute to BL-specific miRNA expression 
profiles which can distinguish between c-Myc positive and negative BL  (Lenze et al., 2011; 
Leucci et al., 2008; Sampson et al., 2007). 
Many lymphoma subtypes, as previously discussed, have a variable association with 
EBV. It is of interest to note that EBV induces the expression of several miRNAs through 
the expression of a number of its latency genes. These include miR-155, miR34a, miR-146a 
and has-miR127 (Cameron et al., 2008; Forte et al., 2012; Gatto et al., 2008; Onnis et al., 
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2012). Further, the differences between the miRNA expression profiles of EBV-positive and 
EBV-negative tumours is distinct (Imig et al., 2011). 
1.3.6 VIRALLY ENCODED MICRORNAS 
A number of viruses have now been identified that encode miRNAs, the first of 
which was EBV (Pfeffer et al., 2004). Currently, more than 40 miRNAs have been identified 
within the EBV genome (Cai et al., 2006; Grundhoff et al., 2006; Zhu et al., 2009).  
EBV encodes these miRNAs within two genomic regions, termed BHRF1 and BART. The 
BHRF1 region produces the viral protein BHRF1, involved in regulation of the lytic phase 
and encodes 3 miRNAs within the intronic regions (Pfeffer et al., 2004). Expression of these 
miRNAs is in part regulated by the Cp and Wp latency promoters (Xing & Kieff, 2011). The 
BART region encodes roughly 40 miRNAs primarily within two large clusters, termed 
Cluster 1 and Cluster 2 which are analogous to the terms BART-A and BART-B used 
throughout the remainder of this thesis (Edwards et al., 2008) (Fig 2). The BART region 
produces many alternatively spliced products and while the BART region has been 
demonstrated to encode functional protein products, expression of these proteins has never 
been demonstrated (Al-Mozaini et al., 2009). The expression of BART miRNAs is 
differentially regulated between different EBV latency profiles and between normal and 
malignant infected cells however, the mechanisms regulating BART miRNA expression is 
currently unknown (Qiu et al., 2011).  
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Figure 2. The location of EBV encoded miRNAs within the EBV genome. Regions of the 
EBV genome encode miRNAs in distinct clusters. Coding regions within the EBV genome 
are indicated by shaded boxes with names above. Positions and names of miRNAs are 
indicated by horizontal bars and arrows A. miRNAs located within non-coding regions of the 
BHRF1 gene. B. Two clusters located in the BART region encoding the majority of EBV 
miRNAs. A single BART miRNA, BART2, is encoded on its own outside of these cluster. For 
the BART region bars above indicate regions cloned into expression constructs termed 
BART-A and BART-B. 
 
While there are several studies investigating the expression of EBV-encoded 
miRNAs in normal and malignant tissues, few studies have investigated the genes that these 
miRNAs target. A small number of genes in both the viral and human genomes have been 
identified as targets repressed by one or more of the EBV-encoded miRNAs. The viral DNA 
polymerase BALF5 is targeted by miR-BART2, binding with perfect complementarity 
(Barth et al., 2008). It is believed that miRNA regulation of BALF5 may play a role in 
regulating EBV‟s lytic cycle. A second viral gene targeted by EBV-encoded miRNAs is 
LMP1, which is a constitutively active homologue of the BCR as described earlier and is 
targeted by several of the BART miRNAs (Lo et al., 2007). While LMP1 is necessary for 
transformation by EBV through the provision of survival signals during EBV-driven 
differentiation, over expression of LMP1 increases the cell‟s sensitivity to apoptosis. 
Reduction in LMP1 expression by miRNA-mediated repression would increase apoptotic 
resistance and as such maintain LMP1 expression. The third viral gene targeted by EBV-
encoded miRNAs is LMP2A (Lung et al., 2009). miRNA-mediated repression of LMP2A is 
believed to aid malignant infected cells in evading the immune system. 
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Few human genes are known to be targeted by EBV-encoded miRNAs and these 
include CXCL11, MICB, PUMA, TOMM22 and IPO7. CXCL11 is a T cell chemoattractant 
targeted by miR-BHRF1-3 (Xia et al., 2008). The functional role of this repression has not 
been investigated but it appears likely that it aids infected cells in avoiding the immune 
system by not signalling T cells. MICB is targeted by miR-BART2-5p (Nachmani et al., 
2009). MICB is a stress induced natural killer (NK) cell ligand and mediates the recognition 
and killing of virally infected cells. EBV (as well as human cytomegalovirus (HCMV) and 
Kaposi‟s sarcoma-associated herpes virus (KSHV) which also encodes miRNAs that target 
MICB) is able to evade NK cell-mediated killing due to miRNA-mediated repression of 
MICB (Nachmani et al., 2009). A third gene known to be targeted by EBV-encoded 
miRNAs is PUMA; a proapoptotic protein able to induce both p53-dependent and 
independent apoptosis depending upon the stimuli (Choy et al., 2008). PUMA is also the 
only other proapoptotic BCL-2 family member aside from Bim that can bind all of the 
antiapoptotic proteins in the BCL-2 family. PUMA is targeted by miR-BART5 and 
repression of PUMA enhances the apoptotic resistance of infected cells. Another study 
identified two new targets of EBV-encoded miRNAs, TOMM22 and IPO7 (Dolken et al., 
2010). These two genes are involved in protein transport and of particular interest, TOMM22 
is believed to be a mitochondrial receptor for Bax, thus playing a key role in regulating 
apoptosis (Bellot et al., 2007).  
Recent studies using chromatin immunoprecipitation assays have identified a 
number of novel potential targets, potentially greatly increasing the pool of known EBV-
miRNA targets (Dolken et al., 2010; Skalsky et al., 2012).  
1.3.7 OVERVIEW OF OUR PREVIOUS STUDY ON EBV-MIRNA FUNCTION 
A prior study conducted by the candidate identified three novel potential human 
targets of EBV-encoded miRNAs; major histocompatibility complex, class II, DO alpha 
(HLA-DOA), Bim and early B cell factor 1 (EBF1) (Appendix 2). 
HLA-DOA, a HLA class II alpha chain paralogue, is a subunit of the heterodimer 
HLA-DO, a chaperone regulating the antigen loading process of MHC class II molecules in 
the lysosomes of B cells (Inoko et al., 1985; Liljedahl et al., 1996). HLA-DO primarily 
serves to inhibit loading of peptide onto MHC class II molecules (Liljedahl et al., 1996; van 
Ham et al., 2000). Dysregulation of HLA-DOA expression is associated with chronic 
lymphocytic leukaemia. The role of HLA-DOA in antigen presentation suggests a potential 
role of EBV-miRNA targeting in immune evasion. While HLA-DO is expressed in both 
naïve and memory cells, HLA-DO expression in germinal centre B cells is virtually 
undetectable (Chalouni et al., 2003; Glazier et al., 2002). 
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Bim is a pro-apoptotic member of the Bcl-2 family expressed in lymphoid cells and 
is one of the major apoptotic proteins regulating the development of B lymphocytes (Bouillet 
et al., 1999; O'Connor et al., 1998). Down regulation of Bim in B cells confers resistance to 
apoptosis induced by cytokine deprivation and abnormal calcium flux (Stang et al., 2009). 
Further, Bim is a major component in the pathogenesis of Burkitt lymphoma, which as 
described above (section 1.3.3.1) is associated with EBV (Leao et al., 2007). Down 
regulation of a pro-apoptotic gene such as Bim would allow infected B cells to evade 
apoptotic signals delivered to aberrant and non functional B cells during B cell development. 
Bim, as well as other members of the Bcl-2 family, have been demonstrated to be targeted by 
EBV. In particular, two EBV latent proteins, EBNA3A and EBNA3C, have been 
demonstrated epigenetically repressing Bim expression. This is accomplished via 
methylation of the promoter region and phosphorylation of the protein, resulting in 
degradation, although subsequent studies have not observed down regulation of Bim via this 
pathway (Anderton et al., 2008; Clybouw et al., 2005; Paschos et al., 2009). 
EBF1 is a transcription factor targeting many B cell specific genes, including B cell 
developmental regulator Pax5 (Hagman et al., 1993; Hagman et al., 1995; Maier & Hagman, 
2002; Travis et al., 1993). The major role of EBF1 is in the determination of early B cell 
fate, and in its absence fully functioning, mature B cells are unable to develop (Maier & 
Hagman, 2002). Studies on the role of EBF1 have focused principally upon the role of EBF1 
in early B cell differentiation. However, both EBF1 and Pax5 are expressed throughout all 
stages of B cell development, with the exception of plasma cells. The role of EBF1 and Pax5 
in the later stages of B cell development is not well understood, although the expression of 
Pax5 is necessary for the maintenance of the B cell phenotype (Rolink et al., 2002a; Rolink 
et al., 2002b; Schaniel et al., 2002a; Schaniel et al., 2002b). E2A is another gene, related in 
function to EBF1 (O'Riordan & Grosschedl, 1999). E2A activates the expression of EBF1 
and many of the functional effects of E2A are caused by the regulation of EBF1. E2A has 
been demonstrated to be necessary in germinal centre development and can induce apoptosis 
within primary effusion lymphoma lines (Kwon et al., 2008; Lietz et al., 2007). Recent 
studies in mouse models have demonstrated that the absence of EBF1 during naïve B cell 
differentiation also impairs germinal centre development and the maturation of B cell 
subtypes (Gyory et al., 2012; Vilagos et al., 2012). 
This previous study identified three potential new targets, one of which was 
confirmed during the course of this study but did not provide further validation of the 
predicted target sites nor the miRNAs responsible for targeting them. This was further 
confounded because two of the target reporter constructs; HLA-DOA and Bim, were not 
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silenced by the predicted miRNA cluster and prompt a further investigation into the 
interactions between the three predicted targets and EBV-miRNAs. 
 Chapter 2: Research Design 14 
Chapter 2: Research Design 
2.1 METHODOLOGY AND RESEARCH DESIGN 
2.1.1 OVERVIEW OF THE METHODOLOGY 
The study was divided into four distinct stages which are directly related to the 
objectives stated in section 1.3. 
2.2 PROCEDURE 
2.2.1 COMPARISON OF HELA AND HEK 293T CELL LINES 
2.2.1.1 CELL CULTURE AND TRANSFECTIONS 
HEK293T and Hela cells were cultured in DMEM (Gibco) and 10% foetal calf 
serum (Gibco) and incubated at 37
o
C, 6.5% CO2. Cells were passaged every 2 to 3 days. 
For luciferase reporter or GFP reporter assays, HEK293T cells were seeded at 
80,000 cells/well in 24 well plates 24 hours prior to transfection. HEK293T cells were 
transfected with a total of 500ng plasmid DNA and 1.5µL Lipofectamine LTX (Invitrogen). 
Hela cells were seeded at 40,000 cells/well in 24 well plates 24 hours prior to transfection. 
Hela cells were transfected with a total of 250ng plasmid DNA, 1.5µL Lipofectamine LTX 
and 0.25µL Plus reagent (Invitrogen). Cells transfected with the GFP reporter pEGFP were 
assayed 24 hours post transfection. Cells transfected for luciferase reporter assays were lysed 
for 48 hours post-transfection. For RNA extractions and subsequent real time PCR 
HEK293T cells were seeded at 320,000 cells/well in 6 well plates 24 hours prior to 
transfection. Cells were then transfected with a total of 2µg plasmid DNA and 6µL 
Lipofectamine LTX and collected 48 hours post-transfection. 
2.2.1.2 CO-TRANSFECTION OF LUCIFERASE REPORTER CONSTRUCTS AND 
MIRNA MIMICS 
HEK293T cells were seeded at 80,000 cells/well in 24 well plates 24 hours prior to 
transfection. Seeded cells were transfected with 250ng firefly luciferase reporter construct, 
50ng pRL-TK, 20pmol negative siRNA or BART11-5p miRNA mimic (Qiagen) and 1.5µL 
Lipofectamine 2000. 
2.2.1.3 GFP REPORTER ASSAYS 
Cells were transfected with the GFP reporter construct pEGFP (500ng in HEK293T 
and 250ng in Hela cells). GFP expression was visualised using the IM1000 Leica DMIRB 
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inverted microscope using bright field to assay cell numbers and fluorescence to determine 
the number of transfected cells. 
2.2.1.4 LUCIFERASE ASSAYS 
Cells were transfected with 5ng of pRL-TK normalising plasmid (Promega), 45ng of 
3‟UTR luciferase reporter construct and 450ng of miRNA expressing construct and 
luciferase activity measured using the Dual-luciferase Reporter Assay System (Promega) 
using either a TopCount NXT luminometer (Perkin Elmer) or a Synergy 4 Plate Reader (Bio 
Tek). Assays were performed in duplicate and experiments were repeated a minimum of 
three times. Firefly luciferase activity was normalised to Renilla luciferase activity and 
expressed relative to cells transfected with empty pcDNA3.1. 
2.2.2 BIOINFORMATIC PREDICTION OF POTENTIAL TARGETS 
In order to predict potential targets of EBV-miRNAs, an in silico analysis was 
performed. This was divided into two approaches which used separate bioinformatic 
algorithms. The first approach was used to identify additional novel targets while the second 
approach was a reanalysis of the data generated by bioinformatic predictions performed 
during the preliminary study. 
2.2.2.1 IDENTIFICATION OF FURTHER NOVEL TARGETS 
Prediction of further novel targets was restricted to a single EBV-miRNA, BART11-
5p. The sequence of BART11-5p was retrieved from miRBase (Accession number 
MIMAT0003421) and inputted into the DIANA microT v3.0 web server using standard 
prediction criteria (Kozomara & Griffiths-Jones, 2011; Maragkakis et al., 2009). DIANA 
microT measures potential targets using several parameters including the base pairing of the 
seed region (nucleotides 1-9) and a secondary region (nucleotides 12-17), evolutionary 
conservation and performs comparative analysis of potential target sites against a set of 
mock miRNAs. Predicted targets were then assessed for their known relationship to EBV by 
performing a literature search in the NCBI Pubmed database using the search term, “target 
gene name” AND (EBV OR Epstein). 
Further analysis of specific target sites was performed by performing bioinformatic 
analysis on targets selected from the Diana microT prediction using two additional 
programs; PITA and RNA22 (Kertesz et al., 2007; Miranda et al., 2006). PITA not only 
identifies potential target sites by a high level of binding at the seed region but also takes into 
account the site accessibility and secondary structure of the surrounding sequence. RNA22 
does not use experimental data but instead uses pattern discovery and has been demonstrated 
to successfully identify non canonical binding sites.  
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2.2.2.2 IDENTIFICATION OF PREDICTED SITES WITHIN TARGETS IDENTIFIED BY 
PRELIMINARY STUDY 
Bioinformatic prediction data that was performed during a preliminary study using 
the algorithms miRanda and TargetScan was re-examined in order to identify potential 
secondary target sites for the potential targets HLA-DOA and Bim. The previous 
bioinformatic data was searched to determine if any other EBV-miRNAs were identified that 
targeted either of these miRNAs that may have been excluded previously by the selection 
criteria. 
2.2.3 DEVELOPMENT OF CONSTRUCTS 
It was necessary to develop several constructs for use in the course of this study 
which expand upon those constructs previously developed. These can be divided into two 
types; luciferase reporter constructs and restricted miRNA expression constructs. 
2.2.3.1 DEVELOPMENT OF LUCIFERASE REPORTER CONSTRUCTS 
Luciferase reporter constructs were developed to cover the MECP2 3‟UTR and site-
specific luciferase reporter constructs were developed for the predicted Bim and EBF1 target 
sites. These site-specific luciferase reporter constructs contained approximately 100bp 
surrounding the bioinformatically predicted target sites in order to preserve any proximal 
elements which may influence miRNA binding. A number of constructs developed during 
the previous study were also used during the current study and are listed in Table 1. 
2.2.3.1.1 PRIMERS AND CLONING PCR 
Target sites and 3‟UTR sequences were cloned from template human gDNA (Roche) 
or, in the case of pGL3-rBART11, from template viral gDNA previously isolated from an 
established EBV transformed lymphoblastoid cell line (QIMR-WIL) using the QiaAmp 
DNA Kit (Qiagen) and inserted into the firefly luciferase reporter construct pGL3-Control at 
the XbaI restriction site. Cloning primers were designed using Primer3 web software (Table 
2) (Rozen & Skaletsky, 2000). Either XbaI or SpeI sites were added to the 5‟ ends of primers 
dependent on the presence of restriction sites within the region to be amplified. Digestion 
with all these restriction enzymes would enable cloning into the XbaI site of the pGL3-
Control vector downstream of the luciferase ORF. 
Cloning was performed with the following PCR reaction, 1x HF Buffer, 0.2µM of 
forward and reverse primers, 0.2mM dNTPs, 1U Phusion Hot Start High-fidelity DNA 
polymerase (Finnzymes) and 30ng of template DNA. The following PCR program was used: 
98
o
C for 30 seconds, 35 cycles of amplification (98
o
C for 5 seconds, 64
o
C for 15 seconds 
and 72
o
C for 1 minute/kb) and 72
o
C for 5 minutes. Correct amplification of sequences was 
confirmed by 1% agarose gel electrophoresis. 
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Table 1: List of constructs developed prior to this study by the candidate. Constructs 
are divided into EBV-miRNA expression constructs and luciferase reporter constructs 
Construct Name 
EBV-miRNA Expression Constructs 
pBART-A 
pBART-B 
Luciferase Reporter Constructs 
pGL3-BCL2L11 
pGL3-EBF1 
pGL3-LMP1 
 
 
Table 2: List of primers used throughout the study to clone DNA from human and viral 
template DNA, screening constructs, synthesis of cDNA and real time PCR. All 
primers were obtained from Sigma-Aldrich. 
Cloning Primers Primer Sequence (5’-3’) 
EBF1-2092-SpeI TAATACTAGTTGGATGCCTTAACAATGCAA 
EBF1-2242-XbaI ATATTCTAGACAGTTCTTTTGTGCTTTTCGAT 
BIM-3254-Spe1 TAATACTAGTATCAGCAGGTGGGAAAGATT 
BIM-3369-Xba1 ATATTCTAGACTAGCCCTGAACAACTGCAA 
BART11-5positiveF1 TAATACTAGTCCACACCTTTGAGGACACCT 
BART11-5positiveR1 ATATTCTAGAACAATAAAGGGCCACACTGC 
MECP2-1401-SpeF1 TAATACTAGTCTGTTTTGAGCCCTGAGGAG 
MECP2-3892-SpeR1 ATATACTAGTCTCTTTCGCCATCACTGTCA 
MECP2-5175-SpeF1 TAATACTAGTAACCCCCATTCTGTCCTACC 
MECP2-6969-SpeR1 ATATACTAGTGAGCAAACACAGCACACGTT 
MECP2-6950-SpeF1 TAATACTAGTAACGTGTGCTGTGTTTGCTC 
18 
18 Chapter 2: Research Design 
MECP2-8498-SpeR1 ATATACTAGTGGGGGTGTTTTTGAAACGTA 
  
Screening Primers Primer Sequence (5’-3’) 
T7 TAATACGACTCACTATAGGG 
BGH-Rev TAGAAGGCACAGTCGAGG 
pGL3F1 GGAAAACTCGACGCAAGAAA 
pGL3R1 CCCCCTGAACCTGAAACATA 
  
cDNA Synthesis Primer Primer Sequence (5’-3’) 
RTQ-primer CGAATTCTAGAGCTCGAGGCAGGCGACATGGCT
GGCTAGTTAAGCTTGGTACCGAGCTCGGATCCA
CTAGTCCTTTTTTTTTTTTTTTTTTTTTTTTT 
  
Real Time Primers Primer Sequence (5’-3’) 
miR-RTQ-Probe AGTGGATCCGAGCTCGGTACCAAGC 
RTQ-uniR2 CGAATTCTAGAGCTCGAGGCA 
U6 CAAATTCGTGAAGCGTTCCATA 
miR-BART4 GACCTGATGCTGCTGGTGTGCT 
miR-BART11-5p GACAGTTTGGTGCGCTAGTTGT 
miR-BART14-3p TAAATGCTGCAGTAGTAGGGATAAAAAA 
 
2.2.3.1.2 RESTRICTION DIGESTS AND LIGATION INTO REPORTER BACKBONE 
PCR products were then purified using QIAquick PCR Purification Kit (Qiagen) and 
digested with the appropriate restriction enzyme (Fermentas) at 37
o
C for 8 hours. pGL3-
Control was digested with XbaI (New England Biolabs) and dephosphorylated with FastAP 
alkaline phosphatase (Fermentas) to prevent re-ligation. Restriction enzymes were heat 
inactivated by incubation at 65
o
C for 20 minutes. Digested products were purified using 
QIAquick PCR Purification Kit (Qiagen) and digestion of pGL3-Control confirmed by 1% 
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agarose gel electrophoresis. Purified PCR products were ligated into vectors using T4 DNA 
ligase (Promega). 
2.2.3.2 DEVELOPMENT OF RESTRICTED MIRNA EXPRESSION CONSTRUCTS 
Additional miRNA expression constructs were developed from the previously 
developed pBART-B construct, which expresses the cluster 2 BART miRNAs. These 
additional constructs expressed restricted subsets of the BART miRNAs (Figure 3). 
2.2.3.2.1 RESTRICTION DIGESTS OF PBART-B 
Two aliquots of the previously developed EBV-miRNA expression construct 
pBART-B were digested; one with XhoI and one with HindIII (New England Biolabs) for 8 
hours at 37
o
C, removing sections of EBV DNA encoding BART miRNAs. Upon the 
completed development of pBART-B3, pBART-B3 was digested with NheI-HF (New 
England Biolabs) in order to develop pBART-B3* in the same manner as pBART-B3. 
Restriction enzymes were heat inactivated at 65
o
C for 20 minutes. 
2.2.3.2.2 PURIFICATION OF DIGESTED DNA FROM AGAROSE GEL 
Digested pBART-B and pBART-B3 was run on 1% agarose gel until two bands 
were visualised, the smaller band a portion of the EBV DNA sequence and the larger the 
pcDNA construct with a portion of the EBV DNA sequence. The larger band was excised 
from excised from the gel and DNA extracted using the QIAquick Gel Extraction Kit 
(Qiagen). Attempts were made to extract the smaller band however, insufficient DNA was 
extracted for further use. 
Figure 3. Schematic of the regions contained in the restricted EBV-miRNA expression 
constructs and the distribution of the EBV-miRNAs therein. The entire region shown is 
expressed by the EBV-miRNA expression construct pBART-B and identifies the miRNAs 
expressed by each EBV-miRNA expression construct. Restriction endonucleases used to 
produce the restricted constructs are also noted.  
20 
20 Chapter 2: Research Design 
2.2.3.2.3 RECIRCULARISATION OF THE MIRNA EXPRESSION CONSTRUCT 
The linearised pBART-B fragment was recircularised using T4 DNA ligase 
(Promega). The HindIII digested construct was termed pBART-B1 and the XhoI digested 
construct was termed pBART-B3. The NheI digested pBART-B3 construct was termed 
pBART-B3*. 
2.2.3.3 HEAT SHOCK TRANSFORMATION INTO E.COLI AND SELECTION OF 
TRANSFORMED COLONIES 
Competent α-Select E.coli (Bioline) was transformed with 2µL of ligation reaction 
using heat shock (42
o
C for 30 seconds) and plated onto LB agar plates containing 50 mg/ml 
ampicillin (Bioline) and incubated 37
o
C overnight.  
2.2.3.4 PCR SCREENING OF CONSTRUCTS 
Clones were screened by PCR for correctly orientated insert using primers within the 
insert and the plasmid. Colonies were directly pipetted in PCR reactions containing 0.5 µM 
of forward and reverse primers, 0.5U Taq DNA polymerase (New England Biolabs), 0.5 mM 
dNTPs, 1x PCR Buffer and 1mM MgCl2 using the following PCR program: 94
o
C for 3 
minutes, 30 cycles of amplification (94
o
C for 15 seconds, 55
o
C for 30 seconds and 72
o
C for 
2 minutes) and 72
o
C for 5 minutes and bands visualised by agarose gel electrophoresis. 
Colonies containing the insert in the correct orientation were then expanded to 5mL 
containing 50 mg/mL of ampicillin. 
2.2.3.5 SEQUENCING OF CONSTRUCTS 
Plasmid was purified from colonies using QIAprep Spin Miniprep Kit (Qiagen), the 
insert region sequenced using BigDye Terminator v3.1 Cycle Sequencing Kit (Applied 
Biosystems) and products submitted to the QIMR Sequencing Facility. Construct sequences 
were confirmed by alignment to the database sequences using the Sequencher 4.7 software 
package (Gene Codes). 
2.2.4 REAL TIME PCR 
2.2.4.1 RNA PURIFICATION  
Cells were dissociated by agitation and collected by centrifugation at 500g for 5 
minutes. RNA was extracted from cell pellets using the mirVana miRNA Isolation Kit 
(Ambion) using the manufacturer‟s instructions for obtaining both miRNA and mRNA. All 
RNA samples were resuspended in nuclease free water (Invitrogen) and stored at -80
o
C 
2.2.4.2 CDNA SYNTHESIS OF MIRNAS 
miRNA-cDNA was synthesised by polyadenylating 500ng total RNA using the 
Poly(A) Polymerase Tailing Kit (Epicentre Biotechnology). In vitro polyadenylated RNA 
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was then purified by phenol-chloroform extraction and ethanol precipitation. First strand 
cDNA synthesis was performed using SuperScript III First Strand cDNA Synthesis Kit 
(Invitrogen) containing the RTQ primer (Table 2), consisting of a poly dT25 3‟ end which 
anneals to the polyadenylated RNA and internal probe binding site and a universal priming 
site at the 5‟ end for use during real time PCR amplification. miRNA-cDNA was diluted to 2 
ng/µL of input RNA for use in real time PCR. 
2.2.4.3 REAL TIME PCR ANALYSIS OF MIRNAS 
For miRNA real time PCR, reactions contained 0.2 µM miRNA miRNA and RTQ-
uniR2 primers, 0.1 µM RTQ-probe (Table 2), 1x GeneAmp II buffer, 1U AmpliTaq Gold 
(Applied Biosystems), 0.2 µM dNTPS (Promega), 2.0 mM MgCl2, 1.0M betaine (Sigma) 
and 5 µL miRNA cDNA.  
Real time PCR was performed in a RotorGene RG-3000 thermal cycler (Corbett 
Research) using the following PCR program: 95
o
C for 10 minutes followed by 45 cycles of 
95
o
C for 15 seconds and 60
o
C for 1 minute with fluorescence acquired at the end of the 60
o
C 
incubation. Relative levels of expression were determined from the amplification curves 
generated during cycling using the Comparative Quantification analysis contained within the 
RotorGene 6 software package (Corbett Research) and calibrating to the expression of EBV 
miRNAs within an EBV-transformed LCL. Expression was normalised to U6 expression. 
2.3 ANALYSIS 
One sample t tests were used to analyse luciferase reporter assays to determine 
whether BART miRNAs were able to significantly silence luciferase expression. Unpaired t 
tests were used to compare the level of silencing of the restricted miRNA expression 
constructs to one another while the variances between experimental replicates were assessed 
using F tests. All p values were two tailed. All statistical analyses were performed using the 
PRISM software package (Graphpad 5). 
2.4 RATIONALE FOR THE STUDY 
The first stage of the study was to establish and optimise the luciferase assay system 
within a new cell line. Preliminary studies were performed in the Hela cell line. Hela cells 
have the advantage of being fast-growing and relatively easily transfectable. In order to 
improve the sensitivity and reproducibility of the luciferase assay system, the luciferase 
assay system was optimised in a new cell line, HEK293T. This cell line was selected because 
it is also fast-growing and easily transfectable, but it has also been transformed with the large 
T antigen from the SV40 virus which drives DNA replication from the SV40 origin of 
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replication. The constructs previously developed all contained the SV40 origin of replication, 
thus the use of HEK293T cells would result in more highly expressed constructs, thereby 
yielding more stable and sensitive assays. 
The transfection efficiencies of Hela and HEK293T cells were compared using a 
GFP expression construct and the variance in luciferase activity between transfections was 
assessed in HEK293T cells compared to previously performed transfections in Hela cells in 
order to validate the improvement in transfections and luciferase assays. Upon optimisation 
of the assay system in the new cell line, the results of the previous work were validated using 
a previously developed positive control based on LMP1, a viral latency gene known to be 
targeted by EBV-miRNAs and EBF1, one of the potential targets identified in the 
preliminary study. 
The second stage of the study was to localise and experimentally demonstrate the 
miRNA-mediated repression of a specific site within the potential targets. The most likely 
target sites were determined using the previously discussed bioinformatic algorithms. 
Truncated luciferase reporter constructs were developed which contained the predicted target 
site. This method of target site localisation was adopted, rather than the alternative method of 
site-directed mutagenesis of the target site for two reasons. The first reason was practical; 
this method is more simple and quicker than site-directed mutagenesis. The second reason 
was to identify sites which may be contributing but not wholly responsible for the miRNA-
mediated repression of luciferase reporters. Previous studies have identified genes which 
contain multiple target sites and require that multiple target sites are bound by miRNAs in 
order to induce translational repression. This seems to be particularly true for EBV-miRNAs 
which act both cooperatively and redundantly. Site-directed mutagenesis of an individual 
target site may not abrogate translational repression in these circumstances while the 
truncation of the luciferase reporters ensures examination of only the target site of interest. 
The third stage of the study focused upon experimentally verifying the miRNAs 
responsible for the translational repression of our target genes. This was achieved by 
generating a suite of miRNA expression constructs which express restricted subsets of EBV-
miRNAs. The expression of mature miRNAs from these constructs was verified using real 
time PCR and a new positive control was developed to demonstrate the specificity of the 
restricted miRNA expression constructs. The miRNA expression constructs were then used 
to validate the miRNAs that were bioinformatically predicted to target the candidate genes. 
Once completed, the target gene luciferase constructs were tested in the same manner against 
a miRNA mimic (Qiagen) of the specific miRNA predicted to target these genes. 
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The fourth stage of the study was to expand the candidate target pool through the use 
of established bioinformatic algorithms. Rather than examining the entire set of ~40 EBV-
miRNAs, the bioinformatic analysis was restricted to a single EBV-miRNA, BART11-5p 
which is the EBV-miRNA predicted to target EBF1. A preliminary bioinformatic analysis 
had been performed on the entire set of EBV-miRNAs and one of the limitations of this was 
that the enormous amount of data generated made applying further selection criteria for the 
most part impractical. By reducing the number of potential targets examined, more stringent 
selection criteria could be applied. 
Three criteria were defined in the selection of potential targets. First, BART11-5p 
would be analysed against a human library of 3‟UTRs using a number of different miRNA 
target prediction algorithms. Many of these algorithms do predict targeting on similar 
criteria, primarily based on the sequence complementarity of the seed region of the miRNA, 
however, there are substantial differences and by analysing BART11-5p against a number of 
them, higher likelihood targets (those predicted by a number of different algorithms) could 
be identified. The second criterion focused upon the specific sites predicted by these 
algorithms. Genes whose predicted sites were identical between different algorithms were 
given higher priority. Additionally, those genes which had multiple target sites predicted 
were also given higher priority. The third selection criterion for novel potential targets was 
an examination of their functional role. Those genes involved in functions known to be 
impacted or altered by EBV (such as genes involved in apoptosis, proliferation, immune 
response and germinal centre differentiation) were selected for further examination. 
Luciferase reporter constructs were developed for likely targets and were then 
validated using the optimised luciferase assay system. 
2.4.1 JUSTIFICATION OF LUCIFERASE SILENCING ASSAYS 
The design of the research study is focused upon elucidating the interaction of 
potential targets previously identified in the Gandhi lab and EBV-miRNAs. The primary 
methodological component utilised throughout the study is the use of a luciferase assay 
system. This approach was selected for several reasons for use in this study. 
First, many of the tools and constructs used during the preliminary study could be 
adapted for use in this study. 
Second, the use of a luciferase reporter system has been widely used in miRNA 
research and miRNA target identification. This system allows for a simple and flexible 
approach that complements the study‟s objectives namely, the further characterisation of the 
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potential targets identified in the preliminary study, both in identifying the specific target site 
and the miRNA(s) targeting these genes. 
Third, the use of a luciferase reporter allows for the examination of targets in an 
easily transfectable system, rather than a slow-growing, difficult to transfect B cell line. In 
addition, the use of luciferase reporters rather than assaying the cognate protein using 
Western blotting, allows the potential targets to be assayed in isolation from many potential 
off-target effects (for example, the alteration of expression of the potential targets by other 
cellular genes rather than miRNA-mediated repression). 
Western blotting is often considered the gold standard technique for the confirmation 
of miRNA targets; although recent studies have begun to use luciferase assays as a final 
means of validating predicted targets (Dolken et al., 2010; Riley et al., 2012). Western 
Blotting was not used in this study for two reasons. The first reason is that Western blotting 
cannot be used to experimentally verify specific predicted target sites within the 3‟UTR, one 
of the primary aims of the study. The second reason was to avoid the use of difficult to 
transfect cell lines, such as many B cell lines, which would potentially require additional 
steps to sort populations of transfected and untransfected cells. 
Newly developed techniques for identifying targets of miRNAs such as HITS-CLIP 
and PAR-CLIP may prove powerful new techniques in the field of miRNA research. These 
techniques are able to identify all potential targets in a single experiment and do not rely on 
current miRNA target prediction algorithms to identify potential targets prior to experimental 
verification. Currently though, these techniques yield a high signal to noise ratio and their 
credentials as an alternative method of miRNA target identification is still being established. 
In addition, these techniques are best suited for use in large studies pursuing the initial 
identification of many potential targets whereas this study was focused upon a small number 
of known potential targets. 
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Chapter 3: Results 
3.1  INTRODUCTION 
 In the introductory chapter, previous research by the candidate was presented that 
identified three potential targets of EBV-miRNAs. This work was limited by the scope of the 
project and technical shortcoming of the previously used reporter assay. This resulted in data 
lacking specificity with regards to demonstration of precise target positions within 3‟UTRs 
and of the EBV-miRNAs targeting these sites. In addition, limitations of the bioinformatics 
approaches used to identify potential targets were presented. This chapter will attempt to 
address these limitations through the establishment of a new reporter assay protocol and 
application of this to the examination of specific target sites and targeting EBV-miRNAs of 
our candidate genes. In addition, through improvement of our bioinformatic approach new 
potential target genes will be established. 
3.2 DEVELOPMENT OF IMPROVED PROTOCOLS FOR MIRNA TARGET 
VALIDATION 
3.2.1 DEVELOPMENT OF AN IMPROVED LUCIFERASE REPORTER ASSAY FOR 
DETECTION OF MIRNA SILENCING  
 The preliminary study performed in this laboratory used Hela cells in transfections 
and luciferase assays to identify potential targets. This section will determine whether 
HEK293T cells provide enhanced sensitivity or reproducibility in comparison to the 
previously used Hela cells. 
3.2.1.1 HEK293T CELLS DEMONSTRATE HIGHER TRANSFECTION EFFICIENCIES 
COMPARED TO PREVIOUSLY USED HELA CELLS 
 To compare suitability for transfection both HEK293T and Hela cells were 
transfected with the green fluorescent protein (GFP) expressing construct pEGFP using 
Lipofectamine LTX (Invitrogen). The percentage of cells transfected and the GFP expression 
level of transfected cells was then assessed using fluorescence microscopy (Figure 4b and 
4c). The transfection efficiency of Hela cells transfected using previously optimised 
transfection conditions was compared to HEK293T cells with varying levels of 
Lipofectamine LTX (Figure 4a). These transfections demonstrate that HEK293T cells are 
more easily transfectable with a 3 fold increase in transfection efficiency and they express 
transfected genes at a much higher level over Hela cells. This supports the use of HEK293T 
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cells over the use of Hela cells. These optimised conditions were used for all subsequent 
experiments. 
3.2.1.2 HEK293T CELLS DEMONSTRATE HIGHER LEVELS AND LOWER 
VARIATION IN LUCIFERASE LUMINESCENCE COMPARED TO 
PREVIOUSLY USED HELA CELLS 
 To determine whether the improved transfection strategy described in 2.2.1.1 results 
in improvements in the luciferase reporter gene assay of miRNA silencing the pGL3-LMP1 
positive control construct was used. This consists of the EBV LMP1 gene 3'UTR fused to 
firefly luciferase. LMP1 mRNA is silenced by EBV-miRNAs within BART Cluster 1 (Lo et 
al., 2007), which is contained within the pBART-A EBV-miRNA expression construct and 
as such co-transfection of pGL3-LMP1 with the pBART-A construct should demonstrate 
silencing through reduced luminescence. 
 To initially determine improvements in reproducibly of luciferase expression the 
pGL3-LMP1 construct was transfected into cells using the two strategies and firefly 
luminescence measured (Figure 5). To clearly examine the effect of transfection strategy on 
the assay luminescence levels from the pGL3-LMP1 firefly luciferase were determined 
without normalisation to the pRL-TK construct. Here a dramatic increase of over 260 fold 
(p<0.0001) in luminescence is observed with the new strategy, likely a result of the 
improved transfection efficiency of these cells and also by the presence of the large T 
antigen discussed in section 3.1. In addition a significant (F-test p=0.0048) reduction in 
variance in luminescence between experimental replicates (from 141 to 11%) is observed 
with the new strategy. These results clearly demonstrate a significant improvement in 
experimental reproducibly with the new strategy. 
 To further determine if this improvement in experimental reproducibility translates 
into improved accuracy of the silencing assay transfections of pGL3-LMP1 were performed 
using both strategies and in the presence of control (pcDNA3.1), pBART-A (positive for 
silencing EBV-miRNAs), pBART-B (negative for EBV-miRNAs) and pRL-TK constructs. 
An examination of the firefly luciferase luminescence in isolation (Figure 6a and 6b) again 
clearly shows the improvement in experimental reproducibility with the new strategy. A 
comparison of the mean expression of the experimental replicates reveals silencing with co-
transfection of the pBART-A construct, however the significance of this result is only 
apparent with the increased reproducibility of the new strategy, where a 46.2% ± 8.1%, 
(p=0.0046) reduction in luminescence was observed. 
 Strikingly for the new strategy a significant 92.5% ± 29.6% (p=0.0355) up-
regulation in firefly luciferase luminescence was observed in cells transfected with pBART-
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B in comparison to cells transfected with an empty miRNA expression construct. To 
determine if this increase is as a result of an unknown impact of pBART-B EBV-miRNAs or 
a potential experimental artefact firefly luminescence was normalised against Renilla 
luminescence from the constantly expressing pRL-TK construct. In this analysis (Figure 6c 
and 6d) increased luciferase levels in the presence of pBART-B are not observed, suggesting 
the previous observation is an experimental artifact caused by inclusion of the pBART-B 
construct into the transfection reaction. 
With normalisation to levels of the negative control (pcDNA3.1) the pGL3-LMP1 positive 
control exhibited a significant reduction in luciferase activity of 39.3% ± 3.0% (p=0.0029) 
when co-transfected with pBART-A and no evidence of repression when co-transfected with 
pBART-B (Figure 6d). The level of repression observed is comparable to that demonstrated 
in the preliminary study, providing further validation of the system.  
 These experiments demonstrate that the use of HEK293T cells is superior to Hela 
cells as it not only improves luciferase expression but reduces the variability between 
experimental replicates, improving the ability to detect miRNA-mediated silencing. While 
miRNA-mediated silencing via the pBART-A miRNAs could be determined without the use 
of a normalising construct, a non-specific increase in luciferase expression by co-transfection 
with pBART-B necessitates the continued use of one.  
  
28 
28 Chapter 2: Results 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Comparisons of the transfection efficiency of Hela and HEK293T cells using 
a GFP reporter demonstrate substantially higher transfection efficiency in HEK293T. 
(A) The transfection efficiency of Hela cells using previously optimised amounts of 
Lipofectamine LTX was compared to HEK293T cells transfected using increasing amounts of 
Lipofectamine LTX. Cells were transfected with the GFP-expressing reporter pEGFP. Bars 
indicate the number of GFP-expressing cells relative to the total number of cells visualised 
using fluorescence microscopy. Bars indicate the mean of three technical replicate from one 
experiment. Error bars indicate SEM of the technical replicates. Examples of GFP-
transfected (B) Hela and (C) HEK293T cells visualised using fluorescence microscopy.
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Figure 5. Use of HEK293T cells improves luminescence levels and reproducibility 
using positive control pGL3-LMP1-UTR construct.  Firefly luminescence of pGL3-LMP1-
UTR reporter construct transfected into HeLa and HEK293T cells. Bars indicate absolute 
levels of firefly luminescence for each cell line transfected. Bars indicate the mean of three 
experimental replicates, each consisting of two technical duplicates. Error bars indicate SEM 
of the experimental replicates. Coefficient of variation of experimental replicates indicated 
above bars for each cell line transfected. 
 
30 
30 Chapter 2: Results 
0 .0
0 .5
1 .0
1 .5
2 .0
2 .5
H eLa H E K 29 3T
p c D N A p B A R T -A p B A R T -B p c D N A p B A R T -A p B A R T -B
F
o
ld
  
fi
r
e
fl
y
 l
u
m
in
e
s
c
e
n
c
e
o
f 
p
G
L
3
-L
M
P
1
-U
T
R
A . B .
0 .69 53
0 .97 15
0 .00 46
0 .03 55
**
*
0 .0
0 .5
1 .0
1 .5
C . D .
p B A R T -A p B A R T -Ap B A R T -B p B A R T -B
H eLa H E K 29 3T
0 .01 50 0 .30 52 0 .00 59 0 .52 81
* **
F
o
ld
 c
h
a
n
g
e
 i
n
 l
u
c
if
e
r
a
s
e
 a
c
ti
v
it
y
 r
e
la
ti
v
e
 t
o
 t
r
a
n
s
fe
c
ti
o
n
 w
it
h
 e
m
p
ty
m
iR
N
A
 e
x
p
r
e
s
s
io
n
 c
o
n
s
tr
u
c
t
 
Figure 6. Use of HEK293T cells improves accuracy of luciferase reporter assay 
detection of miRNA silencing using positive control pGL3-LMP1-UTR and EBV-miRNA 
expression constructs. Firefly luminescence of pGL3-LMP1-UTR reporter construct 
transfected into (A) HeLa and (B) HEK293T cells in combination with pBART-A, pBART-B 
and empty pcDNA miRNA expression constructs. Bars indicate fold level of firefly 
luminescence relative to that of the pcDNA level for each cell line transfected. p-value of 
unpaired t-test against pcDNA for each cell line to demeonstrate significance of change in 
luminescence with miRNA expression constructs indicated above bars. Normalised 
luminescence of pGL3-LMP1-UTR reporter construct against Renilla luminescence of pRL-
TK transfected into (C) Hela and (D) HEK293T cells in combination with pBART-A, pBART-B 
and empty pcDNA miRNA expression constructs. Bars indicate fold level of normalised 
luminescence relative to that of the pcDNA level for each cell line transfected. p-value of one 
sample t-test against 1.0 to demonstrate significance of change in luminescence with miRNA 
expression constructs indicated above bars. Bars indicate the mean of three experimental 
replicates, each consisting of two technical duplicates. Error bars indicate SEM of the 
experimental replicates.   
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3.2.1.3 VALIDATION OF THE POSITIVE CONTROL PGL3-RBART11 
 In addition to the previously developed positive control, pGL3-LMP1, which is 
targeted by several EBV-miRNAs, a new positive control was developed which is 
specifically targeted by either of the BART11 miRNAs, termed pGL3-rBART11. BART11 
is expressed by pBART-B and BART11-5p is the miRNA predicted to target EBF1. pGL3-
rBART11 was co-transfected with pBART-A and pBART-B in order to validate it as a 
positive control (Figure 7). There was no evidence of repression upon co-transfection with 
pBART-A but there was a 25.8% ± 5.8% (p=0.0209) decrease in luciferase expression upon 
co-transfection with pBART-B. These findings provide validation of the newly developed 
positive control pGL3-rBART11. 
3.2.1.4 VALIDATION OF THE LUCIFERASE ASSAY SYSTEM IN HEK293T CELLS 
FOR DETECTING MIRNA-MEDIATED REPRESSION 
 As an additional test of the luciferase assay system in HEK293T cells, the luciferase 
assays which previously identified EBF1 as a potential target were repeated in HEK293T 
cells (Figure 7). No significant silencing was observed when co-transfected with pBART-A 
however highly significant silencing was observed upon co-transfection with pBART-B 
(35.3% ± 4.1%, p=0.0032). This supports the previous findings in Hela cells and provides 
further justification of HEK293T cells as an alternative to Hela cells. 
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Figure 7: Use of HEK293T cells validates a newly developed BART11-5p positive 
control and previous luciferase reporter assays performed in Hela cells in the 
identification of EBF1 as a potential target of EBV-miRNAs. Bars indicate the firefly 
luciferase activity of pGL3-EBF1 and pGL3-rBART11 normalised to the Renilla luciferase 
activity when transfected with either pBART-A or pBART-B miRNA expression constructs 
relative to cells transfected with an empty pcDNA miRNA expression construct. Bars indicate 
the mean of four experimental replicates, each consisting of two technical duplicates. Error 
bars indicate SEM of the experimental replicates. p-value of one sample t-test against 1.0 to 
demonstrate significance of change in luminescence with miRNA expression constructs 
indicated above bars. 
3.3 EXAMINATION AND VALIDATION OF THE PREDICTED TARGET SITES 
OF EBF1 AND BIM 
3.3.1 BIOINFORMATIC PREDICTION OF AN ALTERNATIVE BART MIRNA 
TARGETING BIM 
 Previous bioinformatic analyses discussed in section 1.4.7 identified potential 3'UTR 
target sites for the genes Bim and EBF1 targeted by the EBV-miRNAs BART4 and 
BART11-5p respectively (Table 3). However, preliminary luciferase silencing assays 
demonstrated silencing of the Bim 3‟UTR luciferase reporter by miRNAs from the pBART-
B construct, which does not contain BART4. To determine other potential EBV-miRNAs 
targeting this gene the previous miRanda bioinformatic analysis was re-analysed to identify 
lower scoring target sites within the Bim gene. In addition, the free energy binding of all the 
BART miRNAs against the Bim 3‟UTR was assessed using RNAHybrid (Rehmsmeier et al., 
2004). This re-analysis of the miRanda data set identified a second potential target site at 
position 3290 of the Bim 3‟UTR targeted by BART14-3p which is encoded and expressed 
by the pBART-B miR expressor (Table 3). This site was also identified as a potential target 
of BART14-3p by RNAHybrid (Table 3). 
 33 
Chapter 3: Results 33 
3.3.2 EXPERIMENTAL VERIFICATION OF PREDICTED TARGET SITES WITHIN EBF1 
AND BIM 
 The predicted target sites within EBF1 and Bim were experimentally verified using 
the luciferase silencing assays described in section 2.2.1.4 of the methodology and the site-
specific luciferase reporters pGL3-EBF1-site and pGL3-Bim-site. The site specific luciferase 
constructs contained a 151bp fragment of the EBF1 3‟UTR and a 116bp fragment of the Bim 
3‟UTR, each of which contained the bioinformatically predicted target site in order to assess 
whether the predicted site was responsible for silencing of the luciferase activity observed 
which could not be determined using the full length luciferase reporter constructs previously 
used. No significant reduction in luciferase levels was observed for either predicted target 
site when co-transfected with pBART-A. When co-transfected with pBART-B, the luciferase 
expression of pGL3-EBF1-site was significantly reduced by 43.9% ± 12.7% (SEM) 
(p=0.0258) (Figure 8). The luciferase expression of pGL3-Bim-site was also significantly 
reduced by co-transfection with pBART-B by 78.9% ± 13.1% (p=0.0038) (Figure 8). These 
findings strongly support the functionality of the predicted BART11-5p site at position 2137 
of the EBF1 3‟UTR and by BART14-3p at position 3290 of Bim. 
 
Table 3:  Bioinformatic prediction of target sites within EBF1 and Bim. The first section 
identifies the bioinformatically predicted target sites within the Bim and EBF1 3’UTRs 
predicted in the preliminary study and the second section identifies a secondary target site 
within the Bim 3’UTR identified upon reanalysis of the original bioinformatic data. The 
second column lists the predicted EBV-miRNA targeting the gene and the third column lists 
the predicted site. The fourth and fifth columns provide the score and predicted binding 
energy of the mRNA:miRNA interaction (kcla/mol) calculated by miRanda and the sixth 
column provides the predicted binding energy of the mRNA:miRNA interaction (kcal/mol) 
calculated by RNAhybrid. 
Gene 
Predicted 
miRNA 
Predicted site 
(base pairs 
after CDS) 
miRanda 
score 
Predicted 
binding energy 
(miRanda) 
Predicted 
binding energy 
(RNAhybrid) 
Previously predicted sites 
EBF1 BART11-5p 2137 to 2159 145 -30.12 -33.1 
Bim BART4 1025 to 1049 143 -30.62 -35.7 
Newly predicted sites 
Bim BART14-3p 3290 to 3312 135 -25.54 -28.2 
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Figure 8: Luciferase reporter assays demonstrate the sites in Bim and EBF1 3'UTRs 
targeted by EBV-miRNAs. Bars indicate the firefly luciferase activity of truncated, site-
specific Bim and EBF1-3'UTR luciferase reporter constructs normalised to the Renilla 
luciferase activity when transfected with either pBART-A or pBART-B miRNA expression 
constructs relative to cells transfected with an empty pcDNA miRNA expression construct. 
Bars indicate the mean of five experimental replicates, each consisting of two technical 
duplicates. Error bars indicate SEM of the experimental replicates. p-value of one sample t-
test against 1.0 to demonstrate significance of change in luminescence with miRNA 
expression constructs indicated above bars. 
3.4 DETERMINATION OF SPECIFIC EBV-MIRNA TARGETING OF EBF1 
3.4.1 CONSTRUCTION AND VERIFICATION OF THE EXPRESSION AND SPECIFICITY 
OF MATURE BART MIRNAS FROM RESTRICTED MIRNA EXPRESSION 
CONSTRUCTS 
 In order to specify the miRNA(s) responsible for the repression of pGL3-EBF1-site 
observed in Figure 8, additional miRNA expression constructs were developed to express 
reduced subsets of BART miRNAs (Figure 3). To confirm the functionality of these 
constructs quantitative real time RT-PCR analysis was performed on HEK293T cells 
transfected with the constructs (Figure 9). Neither pBART-B1 nor pBART-B3 demonstrated 
expression of BART4 which is encoded within pBART-A. pBART-B1 expressed both 
BART14-3p and BART13 at levels comparable to an EBV-transformed LCL and did not 
express BART11-5p. In contrast, pBART-B3 expressed BART11-5p at comparable levels to 
an EBV-transformed LCL and did not express BART14-3p. In addition, expression levels 
from pBART-B1 and pBART-B3 were compared to the full pBART-B construct. This 
confirmed the restricted miRNA expression constructs to express miRNAs at comparable 
levels to pBART-B. 
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3.4.2 CONFIRMATION OF A SUBSET OF BART MIRNAS RESPONSIBLE FOR THE 
MIRNA-MEDIATED REPRESSION OF PGL3-EBF1-SITE 
 To clarify which BART miRNAs were targeting pGL3-EBF1-site, luciferase assays 
were performed using the restricted miRNA expression constructs. No silencing of luciferase 
expression was observed with co-transfection of pBART-B1 however, significant levels of 
repression were observed upon co-transfection with both pBART-B3 and pBART-B3* 
(Figure 10). pBART-B3 repressed luciferase expression by 50.6% ± 11.2% (p=0.0458) 
compared to co-transfection of pGL3-EBF1-site with an empty miRNA expression construct. 
pBART-B3* repressed luciferase expression by 37.2% ± 3.0% (p=0.0063). In addition, an 
unpaired t test was performed to compare the level of silencing between co-transfections 
with pBART-B3 and pBART-B3* however there was no significant difference in repression 
between these two constructs. These levels of silencing were comparable to that of the 
positive control pGL3-rBART11 which demonstrated a 47.2% ± 5.2% (p=0.0120) and a 
39.6% ± 8.6% (p=0.0439) level of repression when co-transfected with pBART-B3 and 
pBART-B3* respectively. As both pBART-B3 and pBART-B3* both express BART11-5p 
and there was no statistical difference in the levels of repression between the two miRNA 
expression constructs, these findings provide further support that BART11-5p does repress 
EBF1 at the predicted site. 
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Figure 9: Demonstration of specific miRNA expression from restricted EBV-miRNA 
expression constructs using real time RT-PCR. Real time analysis of EBV-miRNA 
expression from restricted EBV miRNA expression constructs compared to pBART-B. Bars 
indicate expression of EBV-miRNAs from HEK293T cells transfected with either pBART-B, 
pBART-B1 or pBART-B3. miRNA expression levels were normalised to U6 expression and 
reported relative to their expression in an EBV-transformed LCL. One experimental replicate 
was performed with two technical replicates. nd = none detected. 
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Figure 10: Luciferase reporter assays demonstrate miRNA-mediated repression of 
pGL3-EBF1-site by restricted EBV-miRNA expression constructs. Bars indicate the 
firefly luciferase activity of truncated, site-specific EBF1-3'UTR or BART11-specific positive 
control luciferase reporter constructs normalised to the Renilla luciferase activity when 
transfected with miRNA expression constructs expressing restricted subsets of pBART-B 
miRNAs relative to cells transfected with an empty pcDNA miRNA expression construct. 
Bars indicate the mean of three experimental replicates, each consisting of two technical 
duplicates. Error bars indicate SEM of the experimental replicates. p-value of one sample t-
test against 1.0 to demonstrate significance of change in luminescence with miRNA 
expression constructs indicated above bars. 
 
3.5 DETERMINATION OF SPECIFIC EBF1 UTR SITE TARGETED BY EBV-
MIRNA BART11-5P 
In order to test the individual effect of BART11-5p on the predicted target site within the 
EBF1 3‟UTR, luciferase assays were performed using a synthetic miRNA mimic of 
BART11-5p. The miRNA mimic was first validated against pGL3-rBART11 and significant 
repression of luciferase expression was observed using both 10 pmol (67.4% ± 2.0%, 
p=0.0009) and 20 pmol (55.1% ± 2.1%, p=0.0014) of the BART11-5p mimic (Figure 11). 
Luciferase assays were performed with both the full length EBF1 3‟UTR (pGL3-EBF1) and 
the site specific EBF1 reporter (pGL3-EBF1-site). These results demonstrate a statistically 
significant degree of silencing of pGL3-EBF1-site by the BART 11-5p mimic (32.8% ± 
6.4%, p=0.0361). In contrast, the whole EBF1 3‟UTR shows no evidence of repression of 
luciferase activity by BART11-5p (Figure 11).  
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Figure 11: Luciferase reporter assays demonstrate miRNA-mediated repression of 
pGL3-EBF1-site by synthetic BART11-5p mimic. Bars indicate the firefly luciferase activity 
of luciferase reporter constructs normalised to the Renilla luciferase activity when transfected 
with 10pmol of synthetic BART11-5p mimic relative to cells transfected with a negative 
control siRNA. Bars indicate the mean of three experimental replicates, each consisting of 
two technical duplicates. Error bars indicate SEM of the experimental replicates. p-value of 
one sample t-test against 1.0 to demonstrate significance of change in luminescence with 
miRNA expression constructs indicated above bars. 
3.6 APPLICATION OF IMPROVED PROTOCOLS IN THE EXPERIMENTAL 
VERIFICATION OF MECP2 3’UTR PREDICTED TARGET SITE 
3.6.1 IDENTIFICATION OF MECP2 AS A POTENTIAL TARGET OF BART11-5P USING 
BIOINFORMATIC ALGORITHMS 
This study focused on the targeting of BART11-5p, including the development of a BART11 
specific positive control. It was therefore decided that the expansion of the EBV-miRNA 
target pool would be restricted to examining targets of BART11-5p. 
Using the DIANA-microT web server (Maragkakis et al., 2009), 69 genes were identified as 
potential targets of BART11-5p (Appendix 1). These genes were further categorised through 
potential roles in EBV pathogenesis by a literature search. Two potential targets were 
identified as having a potential role; MECP2 and BACH2. MECP2 was selected for 
experimental validation using the luciferase assay system as not only was a prior relationship 
with EBV identified, but it was the top predicted target of BART11-5p by DIANA-microT.  
The specific target sites within the MECP2 3‟UTR were then examined by comparing the 
target sites predicted by DIANA-microT, PITA and RNA22 (Table 3) (Kertesz et al., 2007; 
 39 
Chapter 3: Results 39 
Miranda et al., 2006). Two target sites were predicted by all three algorithms and seven sites 
were predicted by two of the algorithms. The analysis by PITA produced the greatest number 
of predicted sites.  
3.6.2 DEMONSTRATION OF FUNCTIONALITY OF NEWLY IDENTIFIED TARGETS 
 Luciferase silencing assays were performed on the three MECP luciferase reporters, 
which between them covered the highest ranking sites predicted within the MECP2 3‟UTR 
(Figure 12a). Neither pGL3-MECP2a nor pGL3-MECP2b was repressed by co-transfection 
with either pBART-A or pBART-B (Figure 12b). However, pGL3-MECP2c displayed a 
significant 28.36% ± 4.32% (p=0.0224) reduction in luciferase activity when co-transfected 
with pBART-B, which expresses BART11-5p. The predicted site at position 9846 is within 
pGL3-MECP2c and notably, is one of the two sites predicted by all three miRNA prediction 
algorithms. 
The luciferase silencing assays demonstrate that miRNA target prediction can identify 
targets of viral miRNAs. However, it also demonstrates that a large proportion of predicted 
targets cannot be experimentally verified, likely due to many of these predictions being false 
positives. Given that only one predicted target was assessed, it is difficult to gauge the 
efficacy of the prediction tools other than that they are able to identify miRNA targets.  
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Table 4: Analysis of predicted target sites within MECP2 3’UTR. The specific predicted 
sites within the MECP2 3’UTR were analysed using microT v3.0, PITA and RNA22 using 
default settings. The MECP2 sequence was obtained form Genbank accession number 
NM_004992. microT predicted start and end binding sites and binding to the seed region, 
including possible G:U wobbles. PITA predicted the centre of the binding region, the seed 
category (size of the seed:number of mismatches:number of G:U wobbles), the hybridisation 
energy of BART11-5p to the target site (ΔG Duplex) and an overall score (ΔΔG). RNA22 
predicted the start and end binding sites and the predicted binding energy of BART11-5p to 
the target site. Sites marked in bold are predicted by all three algorithms. 
microT 
Start Site End Site Seed Category miTG Score 
2302 2330 7mer(pos 2) 17.02 
3120 3148 7mer(pos 2) 17.02 
3561 3589 8mer(pos 2) 17.02 
3565 3593 7mer(pos 2) 17.02 
7320 7348 7mer(pos 2) 17.02 
9846 9874 8mer(pos 1) 17.02 
10130 10158 8mer(pos 1) 17.02 
PITA 
Predicted Site Seed Category ΔG Duplex ΔΔG 
2318 8:1:0 -19.72 -5.2 
2560 8:1:1 -16.46 1.96 
2860 8:1:1 -12.37 -4.25 
3136 8:1:0 -17.3 -7.23 
3577 8:0:0 -21.06 -13.66 
3581 8:1:0 -21.1 -9.67 
3962 8:1:0 -16.3 -6.6 
4089 8:1:1 -16.5 -8.02 
4981 8:1:1 -14.66 -3.39 
5151 8:1:0 -9.43 -0.89 
5818 8:1:1 -16.3 0.51 
5827 8:1:1 -18.2 0.44 
6971 8:1:1 -12.39 -7.11 
7336 8:1:0 -14.5 -7.29 
8293 8:1:1 -13.2 3.6 
8703 8:1:1 -15 -4.26 
9400 8:1:1 -15.82 -4.46 
9682 8:1:1 -13.4 5.16 
9736 8:1:1 -18.2 -2.15 
9862 8:1:0 -22.8 -4.9 
10146 8:1:0 -17.12 -9.92 
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RNA22 
Start Site End Site Binding Energy 
3120 3143 -25.6 
6917 6940 -27.9 
8688 8711 -26.9 
9721 9744 -27.4 
9846 9869 -25.8 
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Figure 12: Luciferase reporter assays demonstrate that MECP2 is repressed by EBV-
miRNAs by a target site within positions 8637-10185. (A) Schematic representaion of the 
regions of the MECP2 3'UTR tested against EBV-miRNA expression constructs. Sections 
indicate the three regions cloned into luciferase reporter constructs for experimental 
verification. The positition of predicted sites is indicated and predicted sites in bold were 
predicted with all three bioinformatic algorithms. (B) The luciferase reporter assays 
performed on the three MECP2 luciferase reporter constructs. Bars indicate the firefly 
luciferase activity of MECP2-3'UTR luciferase reporter constructs normalised to the Renilla 
luciferase activity when transfected with either pBART-A or pBART-B miRNA expression 
constructs relative to cells transfected with an empty pcDNA miRNA expression construct. 
Bars indicate the mean of three experimental replicates, each consisting of two technical 
duplicates. Error bars indicate SEM of the experimental replicates. p-value of one sample t-
test against 1.0 to demonstrate significance of change in luminescence with miRNA 
expression constructs indicated above bars. 
3.7 CONCLUSION 
This study has improved upon the luciferase silencing assay used in a previous study for the 
identification of targets of EBV-miRNAs by the optimisation of the assay in the HEK293T 
A. 
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cell line, resulting in improved expression and reproducibility, the development of a new 
positive control construct specific to BART11 miRNAs and the development of additional 
EBV-miRNA expression constructs which express restricted subsets of EBV-miRNAs. A 
bioinformatically predicted target site for BART14-3p was identified in the Bim 3‟UTR and 
this site was experimentally verified as being repressed by EBV-miRNAs. Further work was 
performed in investigating EBF1 and not only was the bioinformatically predicted site 
targeted by BART11-5p validated, it was demonstrated that BART11-5p could repress 
luciferase expression via this site, although it was demonstrated that BART11-5p on its own 
is not sufficient for miRNA-mediated repression of the full length 3‟UTR. Finally, a novel 
target of the EBV BART miRNAs was bioinformatically identified and experimentally 
validated; MECP2. 
 Chapter 4: Discussion & Conclusions 45 
Chapter 4: Discussion & Conclusions 
4.1 INTRODUCTION 
 It is becoming increasingly clear that miRNAs occupy an important role in the 
development of disease states such as lymphoma. There is a clear association between 
miRNA deregulation and lymphoma with particular lymphoma types exhibiting distinct 
miRNA expression profiles (Auer, 2011). Burkitt lymphoma can be characterised by the 
absence of miR-155 expression which has been demonstrated to be functionally related to 
the development of c-Myc translocations, a hallmark of BL morphology (Dorsett et al., 
2008; Kluiver et al., 2006). The deregulation of c-Myc expression causes further 
deregulation of miRNA expression including let-7a, miR-17-92, miR-34b, miR-98, miR-331 
and miR-363 (Bueno et al., 2011; Leucci et al., 2008; Mu et al., 2009; Sampson et al., 2007). 
In contrast, in DLBCL mir-155 expression levels are elevated in comparison to normal B 
cells and can distinguish between DLBCL cell of origin subtypes (Eis et al., 2005; 
Malumbres et al., 2009). Further, studies in mouse models highlight the potential role for 
miR-155 as a target of therapy (Babar et al., 2012). In addition, miRNA expression can be a 
strong marker for predicted survival. Several miRNAs including miR-18a, miR181a and 
miR-222 have all been shown to predict survival in DLBCL cases (Alencar et al., 2011; 
Montes-Moreno et al., 2011). 
EBV is associated with several lymphoma types including BL, HL, DLBCL and 
PTLD and each is associated with distinct latency expression profiles (Kuppers, 2003; 
Thorley-Lawson, 2001). The presence of EBV is also known to deregulate several cellular 
miRNAs, notably miR-155, miR-34a, miR-146a and hsa-miR-127, which may contribute to 
its oncogenic potential (Cameron et al., 2008; Forte et al., 2012; Onnis et al., 2012; 
Rahadiani et al., 2008; Yin et al., 2008). Further, the expression of EBV-miRNAs has been 
demonstrated in several lymphoma types although their contribution to lymphomagenesis is 
not known (Nourse et al., 2012; Xia et al., 2008). The expression of BHRF1 miRNAs is 
restricted to latency III expressing lymphomas such as PTLD whereas the expression of 
BART miRNAs has been detected in all tumour and latency types (Cai et al., 2006; Pfeffer et 
al., 2004). The expression of BART miRNAs can vary widely between tumour types (Pratt et 
al., 2009). Further, the expression of several EBV-miRNAs has been demonstrated to be 
deregulated within lymphoma and that tumour type can be distinguished by profiling of 
EBV-miRNAs (Qiu et al., 2011). This suggests that EBV-miRNAs are indeed involved in 
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the pathogenesis of lymphoma and may prove to be useful biomarkers for disease status or 
therapeutic targets. 
The results presented in the previous chapter expand upon preliminary data collected 
by the candidate and outlined in the introductory chapter. The protocols used were refined 
and developed from the preliminary study. The refined protocols were used to elucidate the 
specific target sites of EBV-miRNAs within the Bim and EBF1 mRNA 3‟UTRs and 
evidence was presented implicating BART11-5p involvement in the silencing of EBF1. 
However, the study was not able to demonstrate silencing of the full length EBF1 3‟UTR by 
BART11-5p alone. Finally this study presented evidence of a new potential target of EBV-
miRNAs, the methylated DNA binding transcriptional modulator MECP2. 
4.2 REFINEMENT OF LUCIFERASE REPORTER MIRNA SILENCING ASSAY  
One of the initial goals of this study was the development and refinement of the 
luciferase reporter assay used in our previous work to measure miRNA-mediated gene 
silencing. As demonstrated in section 3.2, this was achieved by optimising the transfections 
within the HEK 293T cell line as compared to the previously used Hela cell line. The HEK 
293T line has been engineered to maintain foreign plasmids that contain the SV40 origin of 
replication at high levels, resulting in higher expression levels (Aydin et al., 2012). Our 
study demonstrates that while miRNA silencing of an LMP1 reporter construct can be 
detected in both Hela and HEK 293T cells and that the level of silencing in each cell line is 
comparable (31% compared to 39%), the reproducibility of the assays is dramatically 
enhanced in HEK 293T cells compared to Hela cells, to the point where the silencing of our 
LMP1 positive control could be demonstrated to significance without normalising to a renilla 
luciferase construct (Section 3.2.1.2, Figure 6). Transfection of the EBF1 3‟UTR luciferase 
reporter construct was also performed in HEK 293T cells to validate the previous findings 
(Ross et al., 2009) and resulted in a comparable level of repression to that measured in Hela 
cells (33% compared to 35%, Section 3.2.1.4, Figure 6). The level of miRNA-mediated 
silencing by EBV-miRNAs is comparable to other miRNA silencing studies  which 
commonly silence 20-60% gene expression dependent upon not only to the complementarity 
of the miRNA binding site, but also due to proximal elements within the 3‟UTR (Grimson et 
al., 2007). There are no published studies which clearly demonstrate any difference in 
miRNA-mediated silencing between Hela and HEK 293T cells, however, studies using 
luciferase reporter assays to investigate promoter regulation and HIV gene expression have 
demonstrated a clear difference in the magnitude of response between Hela and HEK 293T 
cells (Calzado et al., 2004; D. J. Wang et al., 2012), suggesting that while the use of a 
transformed cell line such as HEK 293T can enhance gene expression, it does not enhance 
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the level of miRNA-mediated silencing which is regulated by its ability to bind the target 
site.  
Interestingly, when performing the luciferase assays in HEK 293T cells a significant 
up regulation of luciferase activity upon co-transfection with cluster 2 BART miRNAs 
(encoded in pBART-B) was observed (Section 3.2.1.2, Figure 6b). This up regulation of 
luciferase activity was not specific to the LMP1 3‟UTR construct and was also seen in the 
renilla luciferase normalising construct. One possible explanation of this observation may be 
that the cluster 2 BART miRNAs may be having an indirect effect on luciferase expression 
by repressing targets expressed specifically by the HEK 293T cells. A recent study by 
Shahab et al. demonstrates that many of the alterations in gene expression induced by 
miRNAs are likely not the result of direct targeting but due to the miRNA targeting upstream 
genes and transcription factors (Shahab et al., 2012). It may be that the targeting of genes 
within 293T cells is causing an indirect increase in luciferase expression. While miRNA-
mediated silencing of luciferase expression can be observed without a normalising construct 
with expression of EBV-miRNAs from pBART-A, which does not cause a general increase 
in luciferase expression, the indirect increase caused by pBART-B necessitates the continued 
use of one to detect miRNA-mediated silencing. 
In order to further refine the luciferase silencing assay, a new positive control, 
pGL3-rBART11, was developed. This positive control was regulated specifically by the 
BART11 miRNAs, in contrast to the previously used positive control, pGL3-LMP1, which is 
silenced by multiple BART miRNAs that are expressed by pBART-A. This reporter 
construct was significantly silenced 25% by the EBV-miRNA expression construct pBART-
B and was specifically silenced by all EBV-miRNA expression constructs expressing 
BART11 miRNAs and the BART11-5p miRNA mimic. pGL3-rBART11 was not silenced 
by either pBART-A or pBART-B1, neither of which expressed BART11. However, the 
degree of silencing of the positive control was not expected as the target sequence was 
perfectly complementary to the BART11 miRNAs because target sites with perfect or near 
perfect complementarity are often subject to mRNA degradation instead of translational 
repression and demonstrate very high levels of silencing which is not observed within our 
positive control (Valencia-Sanchez et al., 2006). One potential reason for the lower than 
expected silencing may involve the level of luciferase reporter transcripts being in excess of 
the silencing capacity of the EBV-miRNAs produced from the expression construct. While 
the relative expression of BART11-5p in 293T cells transfected with the EBV-miRNA 
expression constructs was obtained neither the absolute levels of EBV-miRNAs expressed 
by the EBV miRNA expression constructs nor the levels of the luciferase reporter mRNA 
transcript were quantified. Therefore this possibility cannot be ascertained for certain. 
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However, the level of silencing of the BART11 positive control was substantially increased 
up to 67% when co-transfected with the BART11 mimic, suggesting that the miRNA 
expression levels from the miRNA expression construct may have been lower. A further 
confounding result was that increasing the amount of miRNA mimic did not increase the 
level of silencing despite previous studies demonstrating that miRNAs silence target genes in 
a dose dependent manner (Paik et al., 2012). Another potential explanation for the less than 
expected silencing of the control construct involves accessibility to the BART11 target site 
due to secondary structure. It has been demonstrated that a high degree of secondary 
structure around miRNA target sites can abrogate much of the silencing even at sites 
exhibiting near perfectly complementary (Kertesz et al., 2007). As the sequence inserted into 
the positive control construct was the reverse complement of a 150bp region containing the 
BART11 miRNA, and since both pri-miRNAs and pre-miRNAs exhibit a high degree of 
secondary structure, the 3‟UTR of the pGL3-rBART11 positive control may also have had a 
high degree of secondary structure which could potentially interfere with miRNA binding. 
4.3 MIRNA TARGET PREDICTION ALGORITHMS CAN BE USED TO 
IDENTIFY TARGETS OF EBV-MIRNAS  
The use of bioinformatic algorithms in the prediction of potential miRNA:mRNA 
interactions is a key process in the identification of novel miRNA targets. However the high 
levels of both false positive and false negative predictions necessitates careful use of these 
tools. To overcome these obstacles multiple bioinformatic algorithms were used for the 
prediction of potential target sites. It has been demonstrated that different miRNA prediction 
algorithms predict quite distinct sets of miRNA target interactions, and false positives could 
be substantially reduced by examining the overlap of predicted sets, however this is at the 
cost of increasing the number of false negatives (Sethupathy et al., 2006). This finding was 
also observed in our bioinformatic analysis of MECP2. While a number of sites for MECP2 
were predicted, only two were predicted by all three programs used. An additional 
observation in support of the functionality of the two target sites within the MECP2 3‟UTR 
that was positioning at the beginning and end of the 3‟UTR. An analysis by Grimson et al. 
has identified that sites at the beginning and end of 3‟UTRs, particularly long UTRs, are 
more likely to be functional (Grimson et al., 2007). 
Previously verified targets of EBV-miRNAs, such as PUMA and CXCL11, 
demonstrate additional interactions with EBV in addition to regulation by EBV-miRNAs 
(Choy et al., 2008; Kvansakul et al., 2010; McClellan et al., 2012; Xia et al., 2008). From 
this observation an additional criteria was employed to select potential miRNA targets. 
Through an examination of the relationship between the predicted targets and known EBV 
 49 
Chapter 4: Discussion & Conclusions 49 
biology, targets with identifiable functional consequences were selected. Although this 
restricts potential targets to genes which are already known to play a role in EBV 
pathogenesis, given the high number of false positives generated by bioinformatic prediction 
and the small number of verified targets of EBV-miRNAs, this was deemed an acceptable 
limitation.  
Bim was demonstrated to be regulated by EBV-miRNAs within our previous study 
(Ross et al., 2009). The predicted target was with EBV-miRNA BART4, however luciferase 
reporter assays demostrated silencing of the Bim 3‟UTR by the cluster 2 BART miRNAs 
which lacks BART4. Further bioinformatic analysis as described above identified a second 
potential site targeted by BART14-3p. In contrast, a recently published study predicted a 
number of EBV-miRNAs potentially targeting Bim, including BART4 but not BART14-3p 
(Marquitz et al., 2011). This is likely to be due to the different bioinformatic algorithms used 
for miRNA target prediction as our previous study utilised miRanda and TargetScan while 
Marquitz et al. used PITA, emphasising the importance of examining results from multiple 
algorithms. 
4.4 IDENTIFICATION OF A NOVEL TARGET SITE FOR EBV-MIRNAS 
WITHIN THE BIM 3’UTR 
Our previous study identified Bim as a potential target of EBV-miRNAs (Ross et al., 
2009). This result has been confirmed recently, however the precise characteristics of the 
Bim mRNA:miRNA interactions has not been elucidated (Marquitz et al., 2011). Our 
previous study demonstrated a modest 23% reduction in luciferase activity due to cluster 2 
BART miRNAs. However, when luciferase reporter assays were performed on a 116bp 
region containing the predicted BART14-3p site, a substantial 79% reduction in luciferase 
activity was observed (Section 3.3.2, Figure 8). While the reasons for this increase in 
silencing is not clear, a recent study demonstrates the isolation of predicted miRNA binding 
sites from the full 3‟UTR can increase the level of silencing observed (Liang & Wang, 
2012). This effect is both useful and disadvantageous in miRNA target identification as it 
can aid in identifying miRNA targets that are only moderately silenced by miRNA binding 
but can also lead to the contribution of miRNA-mediated silencing to be overestimated.  
Bim is a proapoptotic member of the BH3-only class of the Bcl2 family (O'Connor 
et al., 1998). It plays a crucial role in B cell differentiation and maturation and is a crucial 
regulator of the germinal centre pathway (Craxton et al., 2007; Fischer et al., 2007). As the 
EBV-driven transformation of B cells is believed to drive an atypical germinal centre 
process, (Thorley-Lawson, 2001) Bim is a strong candidate target of EBV-miRNAs from 
purely a functional standpoint. The proapoptotic protein PUMA has been identified as a 
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target of the EBV-miRNA BART5 (Choy et al., 2008). This suggests a role for EBV-
miRNAs in the protection of infected cells from apoptotic stimuli and is consistent with the 
proapoptotic Bim also being a target of EBV-miRNAs.  
During the course of this study Bim was identified as a target of EBV-miRNAs, 
being down regulated by multiple EBV-miRNAs from both BART clusters (Marquitz et al., 
2011). This conflicts with data from our previous study which showed no evidence of 
miRNA-mediated repression of the Bim 3‟UTR by the cluster 1 BART miRNAs, encoded in 
pBART-A (Ross et al., 2009). It has been suggested that there may be unknown EBV-
miRNA target sites within the Bim coding sequence (Marquitz et al., 2011), and as such 
miRNA-mediated silencing via these sites would be detected by Western blotting of protein 
translated from the entire Bim mRNA but would not be detectable by luciferase reporter 
assays, which contain only the 3'UTR. The study by Marquitz et al. also predicted several of 
the specific EBV-miRNAs responsible for the repression of Bim including BARTs 1, 3, 4, 5, 
9, 11 and 12. While they were able to demonstrate a reduction in Bim protein expression for 
some of these miRNAs individually, they were not able to replicate these results using 
luciferase reporter assays. This suggests that EBV-miRNAs may act cooperatively to silence 
gene expression. Studies have demonstrated that the binding of multiple sites within a gene, 
by both the same or different miRNAs, can enhance the level of repression and, in cases, be 
necessary for down-regulation of a target and this may also be the case for Bim (Krek et al., 
2005; Saetrom et al., 2007). An alternative explanation for why silencing of Bim was 
observed in Western blotting experiments but not in luciferase reporter assays performed by 
Marquitz et al. or this study is that EBV-miRNAs have been demonstrated previously to not 
only target Bim, but also numerous other members of the apoptotic pathway (Choy et al., 
2008; Riley et al., 2012). It may be that the effect of EBV-miRNAs on other apoptotic 
members may be regulating the expression of Bim indirectly as well as by a direct miRNA 
interaction.  
Notably, the study by Marquitz et al. did not experimentally verify the predicted 
target sites within the Bim 3‟UTR, nor did they predict BART14-3p as one of the miRNAs 
responsible for targeting Bim. While our study did not conclusively demonstrate the 
targeting of Bim by BART14-3p, it did identify a specific region of the Bim 3‟UTR which 
was predicted as a target site of BART14-3p as sensitive to miRNA-mediated silencing of 
the EBV-miRNAs encoded within pBART-B.  
EBV additionally regulates the expression of Bim through interactions with the EBV 
two latency genes, EBNA3A and EBNA3C (Anderton et al., 2008; Paschos et al., 2009). 
These latency genes epigenetically repress Bim expression via methylation of the Bim 
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promoter (Paschos et al., 2012). The result of EBV latency gene regulation of Bim 
expression by these two distinct mechanisms is unknown at this point; whether the level of 
repression of Bim is additive or synergistic, or whether these two mechanisms are employed 
at different stages during EBV infection in order to keep Bim protein levels at a minimum. 
The expression of EBNA proteins is silenced in memory B cells and the targeting of Bim by 
EBV-miRNAs may function to maintain silencing of Bim in these cells (Babcock et al., 
1998). 
A recent study demonstrated that the predicted target genes of EBV-miRNAs 
overlap to a remarkable degree (Qiu et al., 2011). They posited that EBV-miRNAs are highly 
redundant and cooperative in their targeting. This is also exemplified by studies of other 
targets of EBV-miRNAs. The EBV latency gene LMP1 is targeted by several EBV-miRNAs 
(Lo et al., 2007). The repression of Dicer by the EBV-miRNA BART6-5p has also been 
demonstrated to require multiple, cooperative binding sites (Iizasa et al., 2010). These 
observations are consistent with the targeting of Bim by EBV-miRNAs potentially requiring 
the cooperative targeting (Marquitz et al., 2011).  
4.5 SILENCING OF EBF1 IS MEDIATED THROUGH A NOVEL TARGET SITE 
BY THE EBV-MIRNA BART11-5P 
This study provides evidence of a miRNA target site within the EBF1 3‟UTR, 
2137bp after the stop codon, targeted by the EBV-miRNA BART11-5p. This target site was 
predicted during our previous study (Ross et al., 2009) using three separate miRNA 
prediction tools; miRanda, TargetScan and RNAhybrid (John et al., 2004; Kruger & 
Rehmsmeier, 2006; Lewis et al., 2005). The current work expanded on the previous data 
collected by assessing the level of silencing mediated by the entire EBF1 3‟UTR in addition 
to demonstrating the silencing mediated specifically by a 151bp sequence within the EBF1 
3‟UTR containing the predicted target site. This strongly implicates the predicted target site 
at site 2137 as a functional target of BART11-5p although further experiments, in particular 
site-directed mutagenesis of the predicted target site are necessary to confirm this site as a 
true target of BART11-5p. 
The predicted target site shows a high degree of complementarity to BART11-5p but 
does not exhibit perfect complementarity within the seed region (nucleotides 2-7), containing 
an extra adenosine residue and a G:U wobble. While G:U wobbles demonstrate little 
variation in stability to canonical Watson Crick pairing, studies have demonstrated that a 
single G:U wobbles can significantly interfere with miRNA activity (Doench & Sharp, 2004; 
Varani & McClain, 2000). While the perfect complementarity of the seed region has long 
been considered one of the defining motifs of potential miRNA target sites, extensive 
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binding of the 3‟ region of the miRNA, in particular nucleotides 12-16, can compensate for 
imperfect complementarity of the seed region and a recent study has demonstrated miRNAs 
which bind to sites with a “centred site” motif (Grimson et al., 2007; Shin et al., 2010). This 
study did not explore the specific binding characteristics of BART11-5p to its predicted 
target site but given the degree of pairing, it is probable that the high degree of 
complementarity within the 3‟ region compensates for the imperfect complementarity of the 
seed region. 
The binding between the EBF1 3‟UTR and BART11-5p may also be influenced by 
the post transcriptional regulation of EBV-miRNAs, in particular the generation of isomiRs. 
isomiRs are miRNAs produced from the same pri-miRNA but have a different sequence due 
to post-transcriptional modifications (Neilsen et al., 2012). Deep sequencing of EBV-
miRNAs in nasopharyngeal carcinoma has demonstrated a significant level of sequence 
variation in EBV-miRNAs, although the majority of this variation occurred at the terminal 3‟ 
end of the miRNA, which is not considered critical for miRNA binding and activity (S. J. 
Chen et al., 2010). A previous study has demonstrated the post transcriptional modification 
of the miRNA sequence can alter the miRNA binding and functionality of BART6-5p to 
Dicer, however it is not known how common this is within EBV-miRNAs (Iizasa et al., 
2010).  
It has been demonstrated that several EBV-miRNAs share seed sequences with 
human miRNAs, possibly in order to regulate existing miRNA regulatory networks (S. J. 
Chen et al., 2010). This has been demonstrated in other miRNA-containing viruses such as 
KSHV, which encodes an orthologue to miR-155 (Gottwein et al., 2007; Skalsky et al., 
2007). BART11-5p has been demonstrated to share seed sequence with the human miRNA 
miR-1324 (S. J. Chen et al., 2010). Unfortunately, little is known about miR-1324 and no 
targets have been identified. It was isolated from neuroblastoma samples and, interestingly, 
EBF1 is not only responsible for regulating B cell differentiation but also for regulating 
neuronal differentiation (Afanasyeva et al., 2008; Dubois & Vincent, 2001). 
Although it was demonstrated that a miRNA expression construct expressing cluster 
2 BART miRNAs can silence an EBF1 3‟UTR luciferase reporter (Section 3.5, Figure 11), 
silencing was not observed using a BART11 miRNA mimic. The site-specific construct, 
pGL3-EBF1-site, did appear to be silenced by the BART11-5p mimic with a 28% decrease 
in luciferase activity, although due to time constraints, insufficient replicates were performed 
to demonstrate statistical significance. However, the full length EBF1 reporter showed no 
evidence of silencing by the BART11-5p mimic. As previously discussed, a study by Liang 
and Wang demonstrates that the use of a truncated, site specific reporter can show enhanced 
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levels of silencing in comparison to the full length 3‟UTR (Kertesz et al., 2007; Liang & 
Wang, 2012). However, as the full length EBF1 reporter was silenced by the EBV miRNA 
expression construct expressing all of the cluster 2 miRNAs, it is possible, like other targets 
of EBV-miRNAs, EBF1 is regulated by multiple EBV-miRNAs which have not yet been 
identified. 
Although BART miRNAs are expressed from the same promoter, the levels of 
individual miRNAs differ widely from one another (Qiu et al., 2011). One theory that 
attempts to explain this is that the expression of miRNA targets protects miRNAs from 
degradation, resulting in an increase in the levels of the miRNA (Chatterjee et al., 2011). 
BART11-5p is highly expressed in several tumour types, including NK/T lymphoma and 
DLBCL (Imig et al., 2011; Motsch et al., 2012), which have different cells of origin, 
suggesting a contributing to the pathogenesis of these tumours. In contrast, the expression of 
BART 11-5p within nasopharyngeal carcinoma is barely above background levels (Wong et 
al., 2012). One possible explanation for the difference in the expression of BART11-5p 
between these malignancies could be that NPC contains few miRNA targets for BART11-5p. 
While EBF1 is expressed in both normal and malignant B cells, the expression of EBF1 in 
NPC has not been detected (Gyory et al., 2012; Huang et al., 2012; Lagergren et al., 2004; 
Lukin et al., 2011). A recent study has suggested that while the targets of an individual 
miRNA may be diverse, the functional role of the targets will be similar (Y. Wang et al., 
2011). If EBF1 is indicative of the functional role of BART11-5p targets, namely regulation 
of B cell specific genes, this may suggest that a number of BART11-5p targets may not be 
expressed in NPC and promote degradation of BART11-5p in this malignancy. One flaw in 
this theory is that EBV-miRNAs have been demonstrated to be quite stable in in vitro B cell 
cultures and the mechanism of differential EBV-miRNA expression is largely unknown 
(Amoroso et al., 2011). 
BART miRNAs are also differentially regulated across latent infection. A recent 
study by Qiu et al. investigated the expression of EBV-miRNAs during different latency 
stages of normally infected cells (Qiu et al., 2011). Previous studies have assessed the 
expression of EBV-miRNAs in cell lines expressing different latency programs and have 
demonstrated that EBV-miRNAs are differentially expressed from each other and across 
latency type (Pratt et al., 2009). This has been well-established for the BHRF1 miRNAs 
which are controlled by the Cp promoter and are restricted to latency III or lytic gene 
expression (Amoroso et al., 2011; Cai et al., 2006; Xing & Kieff, 2007). However, BART 
miRNAs are transcribed from the same promoter and it is not known how BART miRNA 
expression is differentially regulated (H. Chen et al., 2005; Kim do et al., 2011). However, 
the study by Qiu et al. has demonstrated that a subset of the EBV-miRNAs is specifically 
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expressed during latency III. Notably in regards to this study, BART11-5p is expressed 
during all forms of latency. This suggests that while some EBV-miRNAs may only play a 
functional role during specific latency stages, BART11-5p, and by extension the targets of 
BART11-5p such as EBF1, are regulated throughout latent infection. 
EBF1 is a crucial transcription factor during early B cell differentiation and an 
important determinant of B cell fate. Although the role of EBF1 during early lymphopoiesis, 
is well established, the function of EBF1 in later B cell differentiation, and thus its potential 
role in EBV pathogenesis, is poorly understood. Recent studies have demonstrated that 
EBF1 is expressed during all stages of B cell differentiation with the exception of plasma 
cells and that EBF1 expression is necessary to the development and maintenance of germinal 
centres (Gyory et al., 2012; Hagman et al., 1993; Vilagos et al., 2012). EBF1 is also known 
to regulate many genes involved in the germinal centre reaction including Pax5, the B cell 
receptor (BCR) and Bim (O'Riordan & Grosschedl, 1999; T. Treiber et al., 2010). In 
addition, the activity of EBF1 is regulated by CD40, a crucial B cell signalling receptor that 
is involved in germinal centre differentiation (Merluzzi et al., 2004). These studies present a 
strong case for the important role EBF1 plays not only in early B cell commitment, but also 
later differentiation steps such as the germinal centre reaction. 
Because EBV-driven transformation of B cells seems to drive an atypical germinal 
centre reaction, the modulation of EBF1 expression by EBV may play a role in this process. 
This is supported by the interaction of EBF1 by EBV latency genes. The EBV latency gene 
EBNA2 has been found to be enriched at EBF1 transcription sites, suggesting that EBNA2 
may associate with EBF1 in order to co-target EBF1-regulated genes (Zhao et al., 2011), 
while LMP2A alters the expression of EBF1 through the Notch signalling pathway 
(Anderson & Longnecker, 2009). In addition to this, binding sites for Pax5, one of the 
primary and most well-characterised targets of EBF1, have been identified in the Wp 
sequence, one of the primary promoters governing EBV latency gene expression and that 
mutation of these binding sites prevents viral activity in B cells (Tierney et al., 2007). This 
suggests a mechanism ensuring B cell specificity of EBV latency expression and highlights 
another possible function of EBF1 targeting by EBV-miRNAs, namely to regulate the 
expression of EBV latency genes. 
Further investigation into the targeting of EBF1 by EBV-miRNAs is warranted. 
Western blotting can be used in conjunction with transfection of EBV-miRNAs to 
demonstrate that the EBF1 protein is silenced in vivo by EBV-miRNAs. Further, the precise 
targeting of EBF1 by EBV-miRNAs needs to be further elucidated and the possibility that 
EBF1 contains target sites for other EBV-miRNAs should be explored. 
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4.6 IDENTIFICATION OF A NOVEL TARGET OF EBV-MIRNAS, MECP2 
The above results identified a novel potential target of EBV-miRNAs, MECP2, a 
DNA methyl-CpG-binding protein which binds specifically to CpG-methylated DNA in 
order to mediate epigenetic regulation (Boyes & Bird, 1991; Jorgensen & Bird, 2002). DNA 
methyl-CpG-binding proteins have been demonstrated to be important in the immune 
response and have been predicted to be targeted by several cellular miRNAs (Vinuesa et al., 
2009). In particular, MECP2 has been demonstrated to target key regulators of B cell 
differentiation, including PU.1 (Suzuki et al., 2003). 
Due to the length of the MECP2 3‟UTR (8.55kb), three reporter constructs were 
developed to cover the 3‟UTR (Section 3.6.2, Figure 12a). While this was performed due to 
limitations of the cloning procedures, it allowed independent assessment of the predicted 
target sites. Analysis of these constructs demonstrated that the majority of the predicted 
target sites (10/16) to be non-functional. Only one of the constructs, MECP2c was silenced 
by EBV-miRNAs expressed by pBART-B (Section 3.6.2, Figure 12b), exhibiting a 28% 
decrease in luciferase activity. This construct contained one of the target sites predicted by 
all of the bioinformatic algorithms used. The other target site predicted by all of the 
bioinformatic algorithms was located in MECP2a, which did not exhibit silencing with either 
of the EBV-miRNA expressing constructs. It is possible that these inactive sites may be 
functional in the correct genomic context. Silencing though the target site in MECP2a may 
have been blocked due to interference from the stop codon. Previous studies have 
demonstrated that target sites within approximately 15 nucleotides of the stop codon are less 
efficiently targeted (Forman & Coller, 2010; Grimson et al., 2007). The predicted miRNA 
target site in pGL3-MECP2a is 30 nucleotides from the stop codon, making this possibility 
seem questionable.  
CpG-methylation of the EBV genome plays a major role in the EBV life cycle, 
regulating the transition from the Wp and Cp promoters during the establishment of latent 
infection (Ernberg et al., 1989; Jansson et al., 1992), as well as regulating the expression of 
several lytic genes (Bergbauer et al., 2010; Kalla et al., 2010). The EBV virion infects cells 
with an unmethylated genome which progressively becomes methylated in order to silence 
the highly immunogenic latency proteins, thus avoiding immune surveillance (Robertson & 
Ambinder, 1997). Given the role methylation plays in EBV gene expression, regulation of 
MECP2 by EBV may modulate the progression of EBV latency.  
MECP2 has been suggested to contribute to segregation in other Herpesviruses. A 
previous study (Lin et al., 2008) observed that MECP2 had a stimulatory effect on plasmid 
maintenance of the EBV genome that was not associated with EBNA1. In addition, MECP2 
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has been demonstrated to bind LANA; a gene equivalent to EBNA1 expressed by the closely 
related Kaposi‟s sarcoma-associated herpes virus (KSHV) (Krithivas et al., 2002; 
Matsumura et al., 2010). 
While this study has demonstrated that MECP2 is a likely target of EBV-miRNAs 
and has bioinformatically predicted a target site within the 3‟UTR for BART11-5p, further 
experiments will have to be conducted to conclusively verify MECP2 as a target of 
BART11-5p and identify the specific target sites within the 3‟UTR. First, it would need to be 
demonstrated that MECP2 is targeted by BART11-5p specifically. Second, site-directed 
mutagenesis will demonstrate the specific site(s) targeted by the EBV-miRNAs. Finally, 
Western blotting will have to be used to demonstrate that BART11-5p can silence MECP2 
protein levels as well as a luciferase reporter. 
4.7 IMPLICATIONS OF FINDINGS FOR EBV PATHOGENESIS 
An understanding of miRNA biogenesis, expression, regulation and functional 
targets are all necessary in order to gain a complete picture of the role of EBV-miRNAs in 
the pathogenesis of EBV.  
The small number of targets of EBV-miRNAs identified does highlight some of the 
functional roles of EBV-miRNAs in the pathogenesis of EBV. The targets PUMA, 
TOMM22 and Bim all demonstrate a clear role in protecting infected cells from apoptotic 
stimuli (Choy et al., 2008; Dolken et al., 2010; Marquitz et al., 2011). In addition, the 
targeting of CXCL11 and MICB suggest a key role of EBV-miRNAs in promoting immune 
evasion (Nachmani et al., 2009; Xia et al., 2008). While comparatively few viral genes are 
targeted by EBV-miRNAs, the regulation of both LMP1 and LMP2A by EBV-miRNAs 
suggest that EBV-miRNAs may be involved in attenuating the transformation of B cells by 
EBV (Lo et al., 2007; Lung et al., 2009). The findings by this study that EBF1 and MECP2 
are targets of EBV-miRNAs may expand upon this function, allowing the virus to subtly 
attenuate the expression of a wide range of genes involved in the B cell differentiation 
process. In addition, the previously demonstrated relationship between EBV and MECP2 
suggest that the regulation of MECP2 by EBV-miRNAs may also be involved in the control 
of EBV replication and the lytic phase in a similar manner to the viral gene BALF5, which is 
regulated by BART2 (Barth et al., 2008). 
The functionality of EBV-miRNAs in the context of viral infection is, for the most 
part poorly understood. One of the well-established laboratory strains of EBV, B95-8, 
contains a large deletion of most of the BART miRNAs and retains the B cell transforming 
capability of EBV (Raab-Traub et al., 1980). Because of this, investigation into the role of 
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BART miRNAs in B cell transformation has been particularly limited. A small number of 
studies have demonstrated that the BHRF1 cluster of EBV-miRNAs has potent transforming 
and growth-promoting effects on B cells (Feederle et al., 2011b; Feederle et al., 2011a; Seto 
et al., 2010). In comparison, only a single study has demonstrated that BART miRNA 
expression has potent effects on growth and cell motility in a gastric epithelial line (Marquitz 
et al., 2012) and there have been no studies conducted investigating the effect of BART 
miRNAs on B cell infection and EBV-driven transformation. This highlights the need for 
further investigation into the effect of BART miRNAs on infected B cells and B cell 
malignancies, particularly as our study has demonstrated that targets of BART miRNAs 
include those which are B cell specific.  
4.8 FUTURE WORK 
This study has focused on the identification and characterisation of novel cellular 
targets of EBV-miRNAs. However, future work investigating the functional effect of 
silencing these genes is critical in the elucidation of EBV-miRNA function. Future work will 
focus particularly on EBF1 and the functional links of this gene with EBV pathogenesis in B 
cells and the potential contribution to lymphomagenesis, as well as the role of EBV-miRNAs 
in regulating EBF1. 
This would first involve profiling the expression of EBF1 targets such as Pax5 and 
determining how much of an effect EBF1 down regulation by EBV-miRNAs has on these 
downstream targets. Given the diverse array of genes that EBF1 regulates, a comprehensive 
investigation of changes in the cellular characteristics due to miRNA-mediated silencing of 
EBF1 will be performed. This will include examining the growth and survival 
characteristics. Because EBF1 regulates transcription of genes involved in BCR and CD40 
signalling and because these signalling pathways are crucial during germinal centre 
differentiation, further functional studies will also examine what effect EBF1 silencing has 
upon these signalling pathways (Gyory et al., 2012; Merluzzi et al., 2004; N. Treiber et al., 
2010; T. Treiber et al., 2010; Vilagos et al., 2012). 
Other known targets of EBV-miRNAs have been demonstrated to be regulated not 
only by the EBV-miRNAs but also by EBV latency genes such as EBNA3C (McClellan et 
al., 2012; Paschos et al., 2012). Given that a recent study has demonstrated a potential 
interaction between EBNA2 and EBF1, an investigation into the possible regulation of EBF1 
by one or more of the EBV latency genes may also be merited (Zhao et al., 2011).  
As previously mentioned, one of the well-characterised laboratory strains, B95-8, 
contains a deletion of the majority of the BART miRNAs. While studies have shown that B 
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cells can be transformed by B95-8 in vitro, a detailed examination of the transformation 
process and a comparison to an EBV strain containing all of the EBV-miRNAs may provide 
additional insights into the function of EBV-miRNAs in a particularly relevant model 
system. 
The effect of EBF1 silencing on lymphomagenesis will also be investigated, 
examining whether EBF1 is differentially expressed in EBV positive and negative 
lymphomas and how this relates to prognosis. 
4.9 CONCLUSION 
In conclusion, this study has identified two novel potential targets, EBF1 and 
MECP2, by EBV BART miRNAs. The role of these genes in the regulation of B cell 
differentiation specific gene expression, suggests that BART miRNAs impact B cell 
differentiation during EBV pathogenesis. 
 The role and function of EBV-miRNAs is still poorly understood although they 
appear to be involved in regulating an array of diverse functions. This is in large part due to 
the small number of known targets. In order to fully comprehend the effect and impact of 
EBV-miRNAs during both initial infection and the development of lymphoma and other 
EBV-related diseases studies, such as this one, which identify novel targets of EBV-miRNAs 
will be vital. 
The identification of host targets of EBV-miRNAs may highlight potential targets in 
the treatment of EBV-associated malignancies by highlighting the pathways by which EBV 
subverts the host immune system. An understanding of EBV-miRNA function may provide 
further insight into predicting disease prognosis and inform treatment options. 
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Appendices 
Appendix 1: Genes predicted as targets of BART11-5p by Diana microT v3.0. Gene 
names are listed in the 1
st
 column. The 2
nd
, 3
rd
 and 4
th
 columns list the measures calculated 
by microT v3.0 in assessing miRNA:target interactions. The miTG score is an overall score 
of the likelihood of a gene being a real target, with a default threshold score of 7.3. Precision 
is a probability measure between 0 and 1 that corresponds to the probability that the target is 
correctly predicted. SNR is the signal to noise ratio and provides a measure of how much the 
predicted target differentiates the background. An asterisk beside the gene name denotes 
targets previously linked to EBV within the literature. 
Gene Name miTG Score Precision SNR 
MECP2* 17.02 0.75 1.76 
SNX1 15 0.54 1.76 
TMCC1 13 0.51 1.76 
NLRC3 13 0.51 1.76 
ADCY6 13 0.51 1.76 
SOX12 12 0.51 1.76 
C1orf69 12 0.51 1.76 
KIAA0430 11.58 0.51 1.76 
ANKRD39 11.04 0.51 1.76 
SYNPO 11 0.51 1.76 
NFBP3 11 0.51 1.76 
CYP4A11 11 0.51 1.76 
CDK5R2 11 0.51 1.76 
ARL6IP1 10.04 0.46 1.76 
KRT74 10.04 0.46 1.76 
NUDCD3 10 0.46 1.66 
HLF 10 0.46 1.66 
CCDC97 10 0.46 1.66 
VPS13B 10 0.46 1.66 
BMPR2 10 0.46 1.66 
PHACTR1 10 0.46 1.66 
CA5B 9.15 0.46 1.62 
PKD1 9 0.46 1.73 
MGAT3 9 0.46 1.73 
SNPH 9 0.46 1.73 
NCAM1 9 0.46 1.73 
MACF1 9 0.46 1.73 
PRKCA 9 0.46 1.73 
MDGA1 9 0.46 1.73 
MEF2D 9 0.46 1.73 
CYBASC3 9 0.46 1.73 
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GPVI 9 0.46 1.73 
PLEKHA6 9 0.46 1.73 
CYP4A22 9 0.46 1.73 
RPL28 9 0.46 1.73 
C18orf1 9 0.46 1.73 
BACH2* 9 0.46 1.73 
SH3RF1 8.63 0.46 1.76 
SIGLEC16 8.04 0.43 1.7 
C21orf128 8.04 0.43 1.7 
MTPN 8.04 0.43 1.7 
FLJ41505 8.04 0.43 1.7 
SYT2 8.04 0.43 1.7 
MESDC2 8.04 0.43 1.7 
BCL9L 8.04 0.43 1.7 
SEPT8 8 0.43 1.7 
GARNL3 8 0.43 1.7 
STK35 8 0.43 1.7 
TAL1 8 0.43 1.7 
CHAC1 8 0.43 1.7 
C14orf21 8 0.43 1.7 
MXD4 8 0.43 1.7 
C11orf45 8 0.43 1.7 
WNT8B 8 0.43 1.7 
C6orf106 8 0.43 1.7 
MAP3K9 8 0.43 1.7 
DNAJC16 8 0.43 1.7 
ZNF772 8 0.43 1.7 
FAM83G 8 0.43 1.7 
GRIN2A 8 0.43 1.7 
IGF2BP1 8 0.43 1.7 
EPT1 8 0.43 1.7 
TRPV3 8 0.43 1.7 
TH 8 0.43 1.7 
MUM1L1 8 0.43 1.7 
DIRAS1 8 0.43 1.7 
TNNI1 8 0.43 1.7 
ACVR2B 8 0.43 1.7 
INPP5F 7.36 0.43 1.69 
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cDNA – complementary DNA 
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DNA – deoxyribonucleic acid 
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DTT – dithiothreitol 
EBV – Epstein Barr virus 
GC – germinal centre 
gDNA – genomic DNA 
GFP – green fluorescent protein 
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LCL – lymphoblastoid cell line 
MHC – major histocompatibility complex 
mRNA – messenger RNA 
miRNA – microRNA 
ORF – open reading frame 
PCR – polymerase chain reaction 
PTLD – post transplant lymphoproliferative disease 
RNA – ribonucleic acid 
RT-PCR – reverse transcription polymerase chain reaction 
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Abstract 
The Epstein Bar virus (EBV) latently infects more than 90% of the world‟s 
population. Although this is predominantly of a benign manner EBV is highly 
associated with several types of lymphoma. EBV infects and activates naïve B-cells 
so that they undergo a germinal centre-like reaction that parallels the activation of a 
naïve B-cell on exposure to an antigen. These different differentiation states are 
reflected in the various type of lymphoma associated with EBV. Recently EBV has 
been demonstrated to expresses several miRNAs, small non coding RNAs which 
negatively regulate the expression of a wide array of genes. miRNAs play key roles 
in regulating developmental pathways and the dysregulation of miRNA expression is 
highly associated with the development of several tumours. EBV miRNAs appear to 
be differentially expressed during the viral life cycle and in various EBV positive 
tumour cell-lines suggesting distinct roles during EBV-driven B-cell differentiation 
and lymphogenesis. Currently few targets of EBV miRNAs have been identified. To 
address the hypothesised that EBV miRNA targeting of human genes regulates B-
cell differentiation and transformation ultimately influencing the pathogenicity of 
EBV, the aim of this study was to identify novel human EBV miRNA targets. Using 
a rigorous bioinformatic analyses potential human gene targets of EBV miRNAs 
were identified and through luciferase reporter assays the down regulation of three of 
these genes was demonstrated. These targets provide novel insights into EBV 
biology. The regulation of HLA-DOA suggests a potential role in immune evasion, 
while that of BCL2L11 would allow infected B cells to evade apoptotic signals. 
Finally the third target, EBF1, is a key B-cell developmental regulator and suggests a 
role in the EBV driven differentiation of B-cells. As these three processes of 
immunomodulation, apoptosis and B cell differentiation would strongly impact on 
EBV infection and lymphomagenesis this study demonstrates EBV miRNA as a 
valuable avenue of research for the understanding and treatment of EBV biology and 
EBV associated lymphoma.  
Introduction 
EBV, a gamma herpes virus, is one of the most successful and prolific human viruses 
infecting >90% of the population. EBV preferentially targets B lymphocytes, and due 
to a number of effective survival strategies is able to evade the host immune system 
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and maintain a persistent and lifelong infection in peripheral memory B cells in a 
latent and benign state (1). However, EBV is also associated with a number of B cell 
malignancies, including; Burkitt‟s lymphoma, Hodgkin‟s lymphoma and PTLD (2-
4). EBV has also been known to infect other cell types and is associated with 
epithelial carcinomas and T cell lymphomas (5). 
Within infected cells, EBV expresses two classes of genes, those associated with the 
lytic cycle resulting in the production of new virus particles resulting in the death of 
the infected cell, and those associated with the latency programs, which are 
expressed in benignly infected cells and do not produce more virus particles(6).  
EBV associated malignancies typically express characteristic latency gene 
expression programs. The expression of latency genes during the establishment of a 
persistent B cell infection is typically divided into four programs, latency 0, I, II and 
III. Latency III, consisting of expression of all latency genes, is found in recently 
infected tonsillar naïve B cells in vivo as well as in B cells infected in vitro and 
results in an activated, proliferating B cell phenotype  (7). Latency II and I programs 
display a more restricted pattern of gene expression(8), while in latency 0 only 
LMP2A is expressed (9-11). The switch from latency III to latency II and then 
latency 0 is believed to allow EBV to establish a persistent infection within 
peripheral memory B cells (3,12). The infected cell is driven through a germinal 
centre like differentiation process by the latency II program and upon differentiation, 
initiating the latency 0 program and ceasing production of most latent proteins to 
generate immunosilent memory B cells(13). A fourth latency program, latency I is 
intermittently expressed by peripheral memory cells to allow replication of the viral 
genome (14). EBV associated lymphomas express latent genes in patterns resembling 
the four latency programs defined, EBV associated Hodgkin‟s lymphoma expresses 
the latency II program and Burkitt‟s lymphoma expresses the latency I program (3) . 
The coordinate expression of latent genes thus regulates the phenotype and 
differentiation of infected cells. In recent years, a class of small non-coding RNAs 
known as miRNAs have been demonstrated to be expressed during latent infection 
(15).  
miRNAs are small, single-stranded RNA molecules which negatively attenuate gene 
expression (16). This is achieved by a number of mechanisms including mRNA 
degradation, deadenylation and, most commonly in humans, translational repression. 
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miRNAs are involved in numerous physiological and pathological processes, 
including development, differentiation and cancer (17).  
 Approximately 40 viral specific miRNAs have been demonstrated to be expressed 
from two regions within the EBV genome (15,18,19) (Figure 1).  The first of these 
clusters is located within introns of the BHRF1 gene and encodes three miRNAs(19). 
These miRNAs appear to be expressed during the latency III program, but not the 
other latency programs. The second cluster is located within a region of complex 
alternatively spliced expression, the BART region (20). The BART region 
potentially encodes functional protein, however this has never been demonstrated to 
be expressed in vivo and the only known products of the BART transcripts are the 
BART miRNAs (15,21). BART encoded miRNAs appear to be expressed during all 
latency stages, as well as in infected epithelial tissue (5,22). 
The majority of studies profiling the expression of EBV miRNAs are performed 
within cell lines of Burkitt‟s lymphoma, nasopharyngeal carcinoma and gastric 
carcinoma(23). Studies have also been performed investigating the expression of 
EBV miRNAs in tumour samples of these cancers. These studies demonstrate that 
the expression of EBV miRNAs in EBV positive cell lines is broadly representative 
of expression in that tumour type. Between cell lines EBV miRNAs are differentially 
expressed. One particular finding is that the BHRF1 miRNAs are diffentially 
expressed between lymphoma and carcinoma samples. BHRF1 miRNAs are not 
expressed in EBV positive carcinomas but are expressed in cells expressing the 
latency III program. Burkitt‟s lymphoma is also known to express BART miRNAs. 
In order to understand how EBV-encoded miRNAs may contribute to the 
development of lymphoma, it is necessary to understand which genes these miRNAs 
target and to what extent, in both the human and viral genome. 
Several studies have already identified targets of EBV-encoded miRNAs. Targets 
within the viral genome include BALF5 and LMP1 (24,25). BALF5 is a viral DNA 
polymerase while LMP1 is a homologue of CD40, a receptor expressed on B cell 
necessary for B cell activation. In addition to miRNA targets within the viral 
genome, several targets of EBV encode miRNAs have been identified within the 
human genome. Three targets within the human genome have been identified, 
PUMA, CXCL11 and MICB (26-28). These targets of EBV-encoded miRNAs 
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possess pro-apoptotic or immunomodulatory functions. The currently identified 
targets of EBV miRNAs are suggestive of the potential role these miRNAs play in 
the development of EBV persistence and in EBV-associated malignancies; further 
targets must be identified in order to elucidate their functionality.  
We believe that EBV encoded miRNAs play a role in the development of long term 
B cell infection and that these miRNAs primarily accomplish this by targeting and 
repressing targeted human genes. These genes are likely to have functions related to 
protecting infected cells from immune recognition and apoptosis and that EBV 
encoded miRNAs may play a role in EBV-induced B cell transformation and 
differentiation. This study aims to identify putative novel targets of EBV miRNA 
mediated repression utilising a simple and effective reporter mechanism. 
Materials and Methods 
miRNA target prediction 
To determine putative targets of EBV encoded miRNAs in the human genome, an in 
silico analysis of mRNA 3‟ UTR sequences was performed. 3‟ UTR sequences from 
the curated non-redundant human Refseq database (29) were compiled using Table 
Browser, an online tool provided by the UCSC Genome Bioinformatics Group 
(http://genome.ucsc.edu/). This library was scanned with each EBV encoded miRNA 
sequence using the miRanda v1.0b software package (30), using a minimum score 
threshold of 130 and a minimum energy (ΔG) threshold of -16 kcal/mol.  
To estimate the level of false positive results, the human 3‟UTR library was analysed 
using the CodonW package (http://codonw.sourceforge.net/) to determine the GC 
content distribution and 1000 sequences of 1kb length reflecting this content 
generated using the FaBox online toolbox 
(http://www.birc.au.dk/~biopv/php/fabox/random_sequence_generator. php).  This 
random library was scanned with the EBV encoded miRNAs as above. Refseq 
targets that scored higher than the random targets for miRanda score and –ΔG were 
selected and run through a second miRNA target prediction program, TargetScan 
(31). Potential target genes that were predicted by both miRanda and TargetScan and 
were then ranked based on miRanda scores and literature relevance to EBV.  
Preparation of Plasmid Constructs 
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EBV miRNA expression plasmids were constructed by cloning regions 
encompassing the primary miRNA sequences into the pcDNA3.1 vector (Invitrogen) 
Primers were designed to amplify three regions from the EBV genome (Accession 
number: AJ507799) using the Primer3 web server (http://frodo.wi.mit.edu/primer3/), 
as shown Table 1 and 2 and Figure 1.  EcoR1 restriction sites were included on the 5‟ 
end of the primers to facilitate cloning into the expression vectors. 
 miRNA clusters were amplified from template viral gDNA previously isolated from 
an established EBV transformed lymphoblastoid cell line (QIMR-WIL) using the 
QiaAmp DNA Kit (Qiagen). PCR was performed with the following PCR reaction, 
1x HF Buffer, 0.2µM of forward and reverse primers, 0.2mM dNTPs, 1U Phusion 
Hot Start High-fidelity DNA polymerase (Finnzymes) and 30ng of template DNA. 
The following PCR program was used: 98
o
C for 30 seconds, 35 cycles of 
amplification (98
o
C for 5 seconds, 64
o
C for 15 seconds and 72
o
C for 1 minute/kb) 
and 72
o
C for 5 minutes.  
Luciferase reporter plasmids were constructed by cloning 3‟ UTR sequences of 
predicted target genes downstream of the luciferase ORF of the pGL3-Control vector 
(Promega). Primers were designed to encompass the miRNA target sites identified 
by the bioinformatic analysis. Either Xba I, Nhe I or Spe I sites were added to the 5‟ 
ends of primers dependent on the presence of restriction sites within the region to be 
amplified. Digestion with all these restriction enzymes would enable cloning into the 
Xba I site of the pGL3-Control vector. PCR products were amplified as described 
above using template human gDNA (Roche).   
Correct amplification of PCR products was confirmed by 1% agarose gel 
electrophoresis. PCR products were purified using QIAquick PCR Purification Kit 
(Qiagen) and digested with the appropriate restriction enzyme (Fermentas). Vector 
DNA was prepared by digestion and dephosphorylation using the appropriate 
restriction enzyme and FastAP alkaline phosphatase (Fermentas) to prevent re-
ligation. Digested products were purified again using the QIAquick PCR purification 
kit and digestion confirmed by 1% agarose gel electrophoresis. Purified PCR 
products were ligated into vectors using T4 DNA ligase (Promega). 
Competent α-Select E.coli (Bioline) was transformed with 2µL of ligation reaction 
using heat shock (42
o
C for 30 seconds) and plated onto LB agar plates containing 50 
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mg/ml ampicillin (Bioline) and incubated 37
o
C overnight. Clones were screened by 
PCR for correctly orientated insert using primers within the insert and the plasmid. 
Colonies were directly pipetted in PCR reactions containing 0.5 µM of forward and 
reverse primers, 0.5U Taq DNA polymerase (New England Biolabs), 0.5 mM 
dNTPs, 1x PCR Buffer and 1mM MgCl2 using the following PCR program: 94
o
C for 
3 minutes, 30 cycles of amplification (94
o
C for 15 seconds, 55
o
C for 30 seconds and 
72
o
C for 2 minutes) and 72
o
C for 5 minutes and bands visualised by agarose gel 
electrophoresis. Colonies containing the insert in the correct orientation were then 
expanded to 5mL containing 50 mg/mL of ampicillin. 
Plasmid was purified from colonies using QIAprep Spin Miniprep Kit (Qiagen), the 
insert region sequenced using BigDye Terminator v3.1 Cycle Sequencing Kit 
(Applied Biosystems) and products submitted to the QIMR Sequencing Facility. 
Construct sequences were confirmed by alignment to the database sequences using 
the Sequencher 4.7 software package (Gene Codes). 
Cell culture and transfections 
HeLa cells were cultured in DMEM (Gibco) and 10% foetal calf serum (Gibco) and 
incubated at 37
o
C, 6.5% CO2. Cells were passaged every 3 to 4 days. For FACS and 
RNA extractions HeLa cells were seeded at 40,000 cells/well in 24 well plates 24 
hours prior to transfection. Cells were transfected using 250ng DNA, 1.5µL 
Lipofectamine LTX and 0.25µL Plus reagent (Invitrogen) and assayed 18-24 hours 
post-transfection. For luciferase reporter assays a modified reverse transfection 
protocol was utilised. A mix of 250ng DNA, 0.5µL Plus reagent and 2.5µL 
Lipofectamine LTX was prepared in 24 well plates and 80,000 HeLa cells were 
added directly to the well and cells assayed 18-24 hours later.  
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Table 1. List of primers used to clone DNA from human and QIMR-WIL EBV gDNA into vectors. 
Restriction sites incorporated into the 5’ ends of primers for cloning are underlined, bases 5’ of these 
sites was included to facilitate digestion. 
Primer 
Name 
Primer Sequence (5’-3’) 
BART-A-Eco-
F1 
ATATGAATTCACTGATAAGGACCGCGGAGT 
BART-A-Eco-
R1 
TTAAGAATTCCTCCAGAGGGCAGACGTTAG 
BART-B-Eco-
F1 
TAATGAATTCTCCCAAATGTCACCACAGAA 
BART-B-Eco-
R1 
ATATGAATTCTCCAACAACCCCATAACGAT 
BHRF1-Eco-F1 TAATGAATTCACAGGCCTAGGGGTCCAG 
BHRF1-Eco-R1 ATATGAATTCTGTGGTAACAGGTGGGACAA 
let7a-Eco-F1 ATATGAATTCTGCATGTAGCCAAAATGTTCA 
let7a-Eco-R1 TTAAGAATTCCACCCCCATCCAGTGTACTT 
LMP1-Xba1-
F1 
ATAATCTAGACCTTTCTTTACTTCTAGGCATTACC
A 
LMP1-Xba1-
R1 
AATTTCTAGACTGTACTTTTATTTATTGCATCACA
AG 
BLIMP1-Eco-
F1 
ATATGAATTCGAGTCAGGGTGCCTGTAGGA 
BLIMP1-Eco-
R1 
TTAAGAATTCCTGACAATTTGCACATAAATAACAT
TG 
LY75XbaF1 TAATTCTAGACCCTGCTAAATGCCATGTTT 
LY75XbaR1 ATATTCTAGACAGCTGTGCTTTTCACATCAA 
CTDSP2XbaF1 TAATTCTAGACAGTAGGGGACTTTCCCACA 
CTDSP2XbaR1 ATATTCTAGACAGTCACAGTGGGAAGCAGA 
MLLXbaF1 TAATTCTAGATGTTTGTGCCCTGTTGACAT 
MLLXbaR1 ATATTCTAGATGACCCATCACAATTCCTCA 
BCL2L11XbaF
1 
TAATTCTAGAAAACCAACAAGACCCAGCAC 
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BCL2L11XbaR
1 
ATATTCTAGAGTAAGCCAGGGAAACTGCAA 
HIF1ANheF1 TAATGGCTAGCGGCACTCCACTCCTATTTGG 
HIF1ANheR1 ATATGCTAGCCCAGATTTTGAAGGGTGGAA 
BCL11ASpeF1 TAATACTAGTGGTTTGACAGAGGGGAACAG 
BCL11ASpeR1 ATATACTAGTAAAGGGACAAAATGGGTGTATG 
EBFSpeF1 TAATACTAGTAACAAAATCACCGACCTTGC 
EBFSpeR1 ATATACTAGTAGGGCAATGTTATGCAATCC 
CD59NheF1 TAATGGCTAGCCTGCGTAGTCCGCTTTCTCT 
CD59NheR1 ATATGCTAGCAGTTAGCAGGAGGCTGGATG 
CD59NheF2 TAATGGCTAGCGCACAAACAACCTCCTGTCA 
CD59NheR2 ATATGCTAGCTTTTTCCCCCTTACTCCAAGA 
HLADOASpeF
1 
TAATACTAGTAAATGACTTGTGGGAGACACC 
HLADOASpeR
1 
ATATACTAGTGAAACACCTTTCCAATGATGC 
CD207XbaF1 TAATTCTAGATGCTTCAAAATTGTCCCACA 
CD207XbaR1 ATATTCTAGATGACCCAGGCAGCATTTTAT 
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Table 2 List of primers used for screening potential constructs and primers used in the synthesis of 
miRNA-cDNA and Real Time PCR 
Screening primers Primer Sequence (5’-3’) 
T7 TAATACGACTCACTATAGGG 
BGH-Rev TAGAAGGCACAGTCGAGG 
EGFP-C-F1 ACATGGTCCTGCTGGAGTTC 
EGFP/DsRed1-R1 TTCAGGTTCAGGGGGAGGT 
pGL3F1 GGAAAACTCGACGCAAGAAA 
pGL3R1 CCCCCTGAACCTGAAACATA 
LMP1-UTR-F1 ACATTTGGATTCAGCCCAAG 
LY75UTR TCCCAAGTGTGGGAACATTA 
CTDSP2UTR AGAAACAAACCAGGCCCAAC 
MLLUTR TCACCTCCCTTCCTCCTTTT 
BCL2L11UTR GGATGAGGCCTGTTTCAAAG 
HIF1ANUTR CCTGGAGGCTCTAGCCAGTT 
BCL11AUTR CAACATGAGTGTGCATTTTCC 
EBFUTR CCTTTGGAGTGACGCATTTT 
CD59UTR2 GTCTGAGGACCAAGGGAACC 
 
cDNA synthesis primer 
 
RTQ-primer CGAATTCTAGAGCTCGAGGCAGGCGACATGG
CTGGCTAGTTAAGCTTGGTACCGAGCTCGGA
TCCACTAGTCCTTTTTTTTTTTTTTTTTTTT
TTTTT 
 
Real time primers 
 
miR-RTQ-Probe AGTGGATCCGAGCTCGGTACCAAGC 
RTQ-uniR2 CGAATTCTAGAGCTCGAGGCA 
U6 CAAATTCGTGAAGCGTTCCATA 
MLL-R1 TCATTTCAGTAACAAATGCAGCTT 
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BCL2L11-F1 CTCATGGGAATTGGCACAG 
HIF1AN-F1 CCAGTGGGACAGTACAGTGTG 
miR-BART1-5p TCTTAGTGGAAGTGACGTGCTGT 
miR-BART1-3p TAGCACCGCTATCCACTATGTCT 
miR-BART4 GACCTGATGCTGCTGGTGTGCT 
miR-BART5 CAAGGTGAATATAGCTGCCCATCG 
miR-BART6-5p GGTTGGTCCAATCCATAGGCTTAAAA 
miR-BART6-3p CGGGGATCGGACTAGCCTTAGA 
miR-BART8-3p GTCACAATCTATGGGGTCGTAGAAAAA 
miR-BART11-5p GACAGTTTGGTGCGCTAGTTGT 
miR-BART11-3p ACGCACACCAGGCTGACTGCC 
miR-BART14-3p TAAATGCTGCAGTAGTAGGGATAAAAAA 
miR-BART15 AGTGGTTTTGTTTCCTTGATAGAAAAAA 
miR-BART20-3p CATGAAGGCACAGCCTGTTACC 
miR-let7a TGAGGTAGTAGGTTGTATAGTTAAAA 
miR-191 CAACGGAATCCCAAAAGCAGCTG 
miR-125b TCCCTGAGACCCTAACTTGTGAAA 
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RNA purification and cDNA synthesis 
Cells were dissociated with 0.25% trypsin in 1mM EDTA and collected by 
centrifugation at 500g for 5 minutes. RNA was extracted from cell pellets using the 
mirVana miRNA Isolation Kit (Ambion) using the manufacturer‟s instructions for 
obtaining both miRNA and mRNA. All RNA samples were resuspended in nuclease 
free water (Invitrogen) and stored at -80
o
C. 
miRNA-cDNA was synthesised by polyadenylating 500ng total RNA using the 
Poly(A) Polymerase Tailing Kit (Epicentre Biotechnology). In vitro polyadenylated 
RNA was then purified by phenol-chloroform extraction and ethanol precipitation. 
First strand cDNA synthesis was performed using SuperScript III First Strand cDNA 
Synthesis Kit (Invitrogen) containing the RTQ primer (Figure 2, Table 2), consisting 
of a poly dT25 3‟ end which anneals to the polyadenylated RNA and internal probe 
binding site and a universal priming site at the 5‟ end for use during real time PCR 
amplification. miRNA-cDNA was diluted to 2 ng/µL of input RNA for use in real 
time PCR. 
Real Time PCR 
For miRNA real time PCR, reactions contained 0.2 µM miRNA miRNA and RTQ-
uniR2 primers, 0.1 µM RTQ-probe (Table 2, Figure 2), 1x GeneAmp II buffer, 1U 
AmpliTaq Gold (Applied Biosystems), 0.2 µM dNTPS (Promega), 2.0 mM MgCl2, 
1.0M betaine (Sigma) and 5 µL miRNA cDNA.  
Real time PCR was performed in a RotorGene RG-3000 thermal cycler (Corbett 
Research) using the following PCR program: 95
o
C for 10 minutes followed by 45 
cycles of 95
o
C for 15 seconds and 60
o
C for 1 minute with fluorescence acquired at 
the end of the 60
o
C incubation. Relative levels of expression were determined from 
the amplification curves generated during cycling using the Comparative 
Quantification analysis contained within the RotorGene 6 software package (Corbett 
Research) and calibrating to the expression of EBV miRNAs within an EBV-
transformed LCL. Expression was normalised to either B2M for mRNA or U6 for 
miRNA. 
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Luciferase reporter assays 
Cells were transfected with 25ng of pRL-TK normalising plasmid (Promega), 25ng 
of 3‟UTR luciferase reporter construct and 200ng of miRNA expressing construct 
and luciferase activity measured using the Dual-luciferase Reporter Assay System 
(Promega) using a TopCount NXT luminometer (Perkin Elmer). Assays were 
performed in duplicate and experiments were repeated a minimum of three times. 
Firefly luciferase activity was normalised to Renilla luciferase activity and expressed 
relative to cells transfected with empty pcDNA3.1. 
Fluorescent reporter system development 
HeLa cells were transfected with pEGFP and pCerulean (32) as described above and 
dissociated using trypsin/EDTA. After centrifugation and washing in PBS cells were 
resuspended in PBS and fluorescence measured using BD FACS Canto II using the 
violet laser (450/50; 502 to 525 nm) and Pacific Blue channel to detect expression 
from Cerulean protein and the blue laser (530/30; 585/42; >670; 780/60 nm) and 
FITC channel to detect GFP expression. Cells were gated against forward and side 
scatter and gated cells were analysed for both GFP and Cerulean expression 
Statistical analysis 
Statistical analyses on both real time PCR and luciferase reporter assays were 
performed using Students and one sample t tests. A Pearson correlation was used to 
analyse the bioinformatic data, and the efficacy of the GFP reporter system was 
assessed using a linear regression. All statistical analyses were performed using the 
PRISM software package (Graphpad).  
Results 
Predicted miRNA targets 
To identify potential targets of EBV encoded miRNAs a bioinformatic process was 
undertaken with results shown in Table 3. Using the miRanda minimum score 
threshold of 130 and energy threshold (ΔG) of -16 kcal/mol individual miRNAs 
exhibited a wide range predicted targets from the RefSeq 3„UTR library (36985 
sequences) ranging from 42 hits for BART14-5p to 1401 for BART12, with an 
average number of 316 targets per miRNA. This variation in the number of predicted 
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targets per miRNA suggested biases within the miRanda algorithm towards certain 
sequences. To gain an understanding of this potential bias an analysis was performed 
using 1000 randomly generated DNA sequences with a G+C content distribution 
matched to that found in the Refseq population. Analysis of this random set by 
miRanda using the same parameters as used for the RefSeq library generated a 
substantial number of hits, with this number of hits exhibiting a significant 
correlation to that found in the RefSeq library for each miRNA (Pearson r =0.8158, 
p<0.0001), suggesting a substantial component of the hits from the Refseq set were 
false positives. Adjusting the number of predicted targets in the random data set to 
that expected in the Refseq set revealed 18 of the miRNAs to have predicted 
proportionally fewer targets from the RefSeq library than from the random 
sequences, again suggesting a high level of false positive hits. These potential false 
positives were removed from the analysis by excluding all RefSeq predicted targets 
with scores and ΔG values below that of the highest ranking hit from the random set 
for each miRNA. This resulted in a significant reduction in the predicted hits as 
shown in Table 3 with numbers ranging from 2 to 66 hits, with an average of 12 hits 
per miRNA.  
To further filter putative targets and increase the rigour of our analysis, a second 
program, TargetScan, was used to analyse RefSeq targets that had been predicted by 
the miRanda analysis. This analysis produced 15 to 446 (average 117) hits per 
miRNA as shown in Table 3. Sequences that had been predicted to have miRNA 
target sites by both miRanda and TargetScan produced a final list of 154 potential 
targets with 0 to 30 hits per miRNA and an average of 5 hits per miRNA as shown in 
Table 4 and listed in Appendix A.. From these genes, 12 potential targets for 
laboratory analysis were selected on the basis of association with either EBV or B 
cell lymphoma pathogenesis and with a function in either B cell differentiation, 
immunomodulation or apoptosis and presented in Table 4. 
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Table 3. The number of predicted targets for each EBV miRNA over the course of the bioinformatic 
analysis. For each EBV miRNA examined (1
st
 column) the number of potential targets predicted by 
the miRanda software from the RefSeq 3’UTR library (2
nd
 column) and from a library of randomly 
generated sequences (3
rd
 column) is indicated. To obtain measure of false positive target prediction 
the number obtained from the random library was subtracted from the number obtained from the 
RefSeq library (th column). The number of potential targets from the RefSeq library exhibiting scores 
above those observed in the random library are shown in the 5
th
 column. The 6
th
 column indicates 
potential targets identified by inputting the positive 3’UTRs identified by miRanda in a second 
program TargetScan. Final putative targets identified by both miRnada and TargetScan analyses are 
shown in the 6
th
 column. 
miRNA Name 
miRanda 
TargetScan 
RefSeq hits 
Hits 
common to 
miRanda 
and 
TargetScan 
RefSeq 
hits 
Random 
hits 
RefSeq 
minus 
Random 
hits 
RefSeq 
hits 
above 
Random 
scores 
miR-BHRF1-1 103 111 -8 8 98 5 
miR-BHRF1-2 287 0 287 21 216 15 
miR-BHRF1-3 333 555 -222 7 15 1 
miR-BART1-5p 779 999 -220 7 92 4 
miR-BART1-3p 160 185 -25 4 67 2 
miR-BART2 242 148 94 13 446 9 
miR-BART3-5p 208 370 -162 3 66 2 
miR-BART3-3p 134 148 -14 16 20 3 
miR-BART4 240 370 -130 5 99 4 
miR-BART5 603 703 -100 7 135 5 
miR-BART6-5p 353 185 168 5 58 2 
miR-BART6-3p 66 222 -156 8 33 3 
miR-BART7 211 333 -122 5 108 1 
miR-BART8-5p 197 518 -321 5 17 0 
miR-BART8-3p 128 333 -205 6 131 3 
miR-BART9 135 222 -87 5 98 2 
miR-BART10 364 222 142 13 123 7 
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miR-BART11-5p 232 407 -175 4 109 4 
miR-BART11-3p 113 74 39 41 38 2 
miR-BART12 1401 1368 33 7 177 5 
miR-BART13 380 296 84 6 68 2 
miR-BART14-5p 42 111 -69 2 24 0 
miR-BART14-3p 519 407 112 5 188 4 
miR-BART15 501 259 242 18 82 4 
miR-BART16 366 370 -4 3 78 1 
miR-BART17-5p 281 222 59 5 157 4 
miR-BART17-3p 122 148 -26 8 157 2 
miR-BART18 89 74 15 4 124 2 
miR-BART19 629 259 370 11 330 8 
miR-BART20-5p 333 74 259 66 104 19 
miR-BART20-3p 232 0 232 48 178 30 
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Construction of Plasmids for miRNA Reporter Assays 
To determine functionality of the selected putative miRNA targets, reporter gene 
assays were employed. Two approaches were trialled, first a luciferase assay system, 
in which the 3‟ UTR region targeted by the miRNA is fused to the coding region of 
the firefly luciferase gene within an expression construct. Co-transfection of this 
construct with or without the overexpression of the EBV miRNA is assayed for 
luciferase activity and if the miRNA actually targets the putative site a reduction in 
activity should be observed when the miRNA is expressed (Figure 2). An alternate 
approach examined was the use of a green fluorescent protein (GFP) as a reporter 
with fluorescence assayed using FACS. It was hoped that this method would result in 
a more affordable, rapid and accurate method as processing of cells and expensive 
assay reagents would not be required. In addition, GFP levels would be normalised 
within cells with a second, normalising cyan fluorescent protein (Cerulean) enabling 
more accurate assays. 
Constructs were developed as listed in Table 5. As time constraints did not allow 
completion of the BHRF1 miRNA expressing construct analysis of the two BHRF1-2 
targets, SLAMF6 and PIGR was excluded from further study and reporter constructs 
for these targets were not developed. 
A positive control for miRNA silencing was developed using 3‟UTR of LMP1. 
Studies have demonstrated that LMP1 is targeted by several miRNAs encoded in the 
BART region, specifically miRNAs encoded within the BART-A cluster (ref). An 
additional positive control was developed for the GFP system. The BLIMP1 3‟ UTR 
was inserted into pEGFP and used for the reporter construct and coupled with a 
miRNA expressing construct that expresses let7a, a human miRNA known to target 
BLIMP1 (ref). LMP1 was to be used as a second positive control for the fluorescent 
system as well but due to time constraints, this construct could not be completed. An 
additional rationale for the utilisation of BLIMP1 as a positive control was 
preliminary data obtained in our laboratory that it may be targeted by EBV miRNAs, 
as evidenced by an inverse correlation between BLIMP1 and EBV encoded miRNA 
expression (Nourse, J. pers. comm.). 
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Table 4 Potential targets of EBV miRNAs that were selected for testing with reporter assays. 
Genbank accession numbers of gene nucleotide sequences are indicated in the 1
st
 column while the 
name of the gene is indicated in the 2
nd
 column. miRanda scores of the predicted miRNA binding 
sites are indicated in the 3
rd
 and 4
th
 columns, while the names of the EBV-miRNA predicted to target 
the gene is indicated in the 5
th
 column. The miRNA expression construction containing the predicted 
miRNA targeting the gene is indicated in the 6
th
 column..  
Accession # Target Gene 
miRanda 
score 
miRanda 
energy 
EBV miRNA 
miR 
expressor 
NM_002349 Lymphocyte antigen 75 146 -29.34 BART1-5p BART-A 
NM_024007 early B-cell factor 1 145 -30.12 BART11-5p BART-B 
NM_005730 
CTD (carboxy-terminal 
domain, RNA polymerase II, 
polypeptide A) small 
phosphatase 2 
144 -32.75 BART4 BART-A 
NM_006538 
BCL2-like 11 (apoptosis 
facilitator) 
143 -30.62 BART4 BART-A 
NM_052931 SLAM family member 6 142 -19.71 BHRF1-2 BHRF1 
NM_002644 
polymeric immunoglobulin 
receptor 
142 -19.33 BHRF1-2 BHRF1 
NM_203331 
CD59 molecule, complement 
regulatory protein 
141, 139 
-23.25, 
-30.36 
BART10, 
BART13 
BART-B 
NM_017902 
hypoxia-inducible factor 1, 
alpha subunit inhibitor 
139, 132 
-33.21, 
-26.39 
BART5, 
BART11-3p 
BART-A 
BART-B 
NM_005933 
myeloid/lymphoid or mixed-
lineage leukemia 
139 -32.09 BART5 BART-A 
NM_002119 
major histocompatibility 
complex, class II, DO alpha 
139 -29.87 BART8-3p BART-B 
NM_015717 CD207 molecule, langerin 136 -28.08 BART20-3p BART-B 
NM_022893 
B-cell CLL/lymphoma 11A 
(zinc finger protein) 
136 -23.04 BART15 BART-A 
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Table 5 List of constructs developed in this study. Names of constructs made are indicated with 
regions of sequence inserted shown in the second column. For EBV miRNA expression constructs 
regions are relative to the EBV genome (Genbank accession AJ507799), for the let7a construct region 
are relative to Genbank accession NT_008470.19. For luciferase reporter constructs regions are 
relative to Genbanks accession indicated in table 4. 
Name Region inserted 
miR NAexpressor 
constructs 
 
pBART-A 138811-140361 
pBART-B 145576-149262 
plet7-a 26102590-26103019 
Luciferase-3’UTR 
reporter constructs 
 
pGL3-LMP1 166476-167701 
pGL3-LY75 5396-6873 
pGL3-CTDSP2 1375-4853 
pGL3-MLL 13565-14964 
pGL3-BCL2L11 753-4790 
pGL3-HIF1AN 1290-5348 
pGL3-BCL11A 3976-5917 
pGL3-EBF1 2215-5040 
pGL3-CD59a 586-1512 
pGL3-CD59b 5824-7569 
pGL3-HLA-DOA 845-3428 
pGL3-CD207 1142-1864 
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Verification of miRNA Expression Constructs  
Expression of miRNAs from the BART miRNA expressing constructs was 
confirmed using real time RT-PCR analysis of RNA extracted from transfected HeLa 
cells. A representative sample of miRNAs from both the BART-A and BART-B 
clusters were selected for analysis. This analysis demonstrated that both pBART-A 
and pBART-B expressed mature BART miRNAs when transfected into HeLa cells 
and that the real time RT-PCR method employed for detection was specific (Figure 
3). The levels of BART miRNAs expressed were comparable to those observed from 
an EBV-transformed LCL. An examination of miRNA expression levels revealed 
duplexes such as BART1-5p and BART1-3p, which are encoded in a single pre-
miRNA, exhibited an asymmetry in expression, consistent with current notions of 
miRNA processing and loading of the RISC complex. Relative to the LCL, BART-A 
miRNAs were generally expressed at higher levels with BART1-5p, BART1-3p and 
and BART4 all exhibiting higher expression in pBART-A transfected HeLa cells 
than they do in LCL. In contrast, BART-B miRNAs appear to express at lower levels 
in HeLa cells than in LCL. This may be due to the relative length of the BART 
inserts, the BART-B insert is more than twice as long as the BART-A insert. The 
extra length of the BART-B transcript may slow transcription and processing of 
mature miRNAs, leading to lower levels of expression. 
In comparison to the EBV miRNA constructs, examination of the let7-a expressing 
construct (plet7-a) revealed that expression of mature let7-a was significantly 
reduced in HeLa cells transfected with this construct as compared to cells transfected 
with an empty pcDNA3.1 vector (Figure 4). 
As let7-a has been demonstrated to target the nuclease Dicer required for miRNA 
maturation(33), expression levels of two human miRNAs hsa-mir191, and hsa-
mir125b were examined to determine if reduced let-7a levels were as a result of 
general miRNA deregulation through silencing of Dicer. Neither hsa-mir191 nor hsa-
mir125b showed any statistically significant decrease in expression in plet7-a 
transfected cells. However, the real time analysis of human miRNAs was only 
performed twice and statistical significance may have been detected with further 
replicates.  
Fluorescent protein reporter system can quantitate GFP fluorescence 
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To demonstrate the feasibility of the use of GFP as a reporter HeLa cells were 
transfected with a gradient of pEGFP-C2 vector in combination with a fixed amount 
of the cerulean fluorescent protein expressing vector pCerulean and analysed by 
FACS. The average fluorescence of pEGFP-C2 transfected cells when normalised to 
the average fluorescence of Cerulean protein, exhibited a linear increase in 
fluorescence with increasing amounts of pEGFP-C2 (Figure 5) suggesting the system 
would be capable of detecting changes in GFP fluorescence resulting from miRNA 
mediated down regulation. Optimisation and testing of this assay system was not 
developed further due to time constraints. 
Controls demonstrate luciferase reporter system is functional 
To demonstrate the ability of the luciferase reporter system to detect miRNA 
mediated silencing pGL3-LMP1 was co-transfected with either the pBART-A or 
pBART-B miRNA expression constructs and cells assayed for changes in luciferase 
activity. As mentioned above LMP1 has been demonstrated to be specifically 
targeted by EBV miRNAs encoded within the BART-A construct and as expected, 
cells cotransfected with pGL3-LMP1 and pBART-A exhibited a 31.1% ± 6.7% 
(p=0.0185) decrease in luciferase activity, in contrast to pBART-B, which did not 
decrease expression (Figure 4 and Table 6). 
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Table 6 Statistics of the LMP1 positive controls and negative controls within the luciferase assay 
system. The 1
st
 column indicated the combination of reporter/miRNA expressor combinations used 
in transfections. The 2
nd
 column indicates the mean of luciferase activity of the transfections 
containing the miRNA expressor as compared relative to the transfections containing the empty 
pcDNA3.1 vector, whose activity was arbitrarily defined as 1.0, with the SEM in the 2
nd
 column (n=3). 
As all values for the transfections with empty pcDNA3.1 were assigned a value of 1.0 a one-sided T-
test was performed to determine significance of the fold change with expression of the miRNA 
against the 1.0 value as indicated in the 3
rd
 column. A determination of the significance result as 
outputted by the Prism software is indicated in the 5
th
 column. 
 
Mean Std. Error 
P value 
(two tailed) 
Significant 
(alpha=0.05)? 
LMP1/BART-A 0.6895 0.06646 0.0185 Yes 
LMP1/BART-B 1.017 0.08498 0.8574 No 
GL3/BART-A 1.248 0.3693 0.571 No 
GL3/BART-B 1.011 0.0518 0.8641 No 
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To ensure that the BART-A miRNAs were down regulating luciferase expression via 
target sites in the LMP1 3‟UTR and not cryptic sites within the pGL3-Control 
plasmid sequence, an identical experiment was performed with pGL3-Control in 
place of pGL3-LMP1. The luciferase activity in this experiment remained constant 
across all samples and did not exhibit any change in expression due to BART 
miRNAs. The pGL3-Control/pBART-A assay was only performed twice in contrast 
to the other assays which were performed three times, due to an error during 
transfection. 
Examination of EBV miRNA expression on putative targets identified three 
potentially targeted genes (HLA-DOA, BCL2L11 and EBF1) 
To determine the functionality of the putative BART miRNA targets identified above 
luciferase reporter assays were performed and the results shown in Figure 6 and 
tables 7 and 8. For the six selected genes predicted to be targeted by miRNAs 
contained within the BART-A cluster no significant alteration in expression was 
observed when the pBART-A construct was co-transfected with the reporter 
constructs. 
Interestingly when the BART-A target reporter constructs were cotransfected with 
pBART-B a highly significant, reproducible reduction (23.2% ± 1.7%, p=0.008) in 
luciferase activity was observed for the BCL2L11 construct (Figure 6). In addition, 
pGL3-MLL exhibited a large yet statistically insignificant reduction in luciferase 
activity (30.3% ± 11.4%, p=0.0763), when BART-B miRNAs were overexpressed. 
The lack of statistical significance may be due to variation in experimental replicates 
and may be overcome through further optimisation of transfections and assays and 
further replicates may identify MLL as a target of BART-B miRNAs. For the five 
selected genes predicted to be targeted by BART-B miRNAs, the EBF1 construct 
was the only target that exhibited a significant reduction in luciferase activity (33.2% 
± 7.2%, p=0.0192) due to expression of BART-B miRNAs (Figure 6). Again 
unexpectedly a third significant target was identified when the predicted BART-B 
targets were assayed with the expression of BART-A miRNAs. The HLA-DOA 
construct exhibited a significant reduction in luciferase activity (21.49% ± 6.7%, 
p=0.0485).  
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Two of the three positive results were not predicted by the bioinformatic analysis. 
While EBF1 was predicted to be targeted by a miRNA within the BART-B cluster, 
neither HLA-DOA nor BCL2L11 were down regulated by their predicted BART 
miRNA clusters. To determine the previously undetermined sites underlying this 
down regulation the bioinformatic data was reanalysed for these two gene‟s 3‟ UTRs. 
This revealed a second potential target site within the BCL2L11 3‟ UTR for 
BART14-3p, a miRNA within the BART-B cluster. This target site had been 
excluded during filtering of the results using random 3‟ UTRs. No secondary target 
site was identified for the HLA-DOA 3‟ UTR within the miRanda bioinformatic scan 
and the miRNAs targeting these genes and potential target sites remain unknown. 
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Discussion 
The role of virally encoded miRNAs in the biology of EBV is currently not well 
understood. The aim of this study therefore was to identify novel human targets of 
EBV encoded miRNAs to provide new insights into the role of these regulatory 
molecules.  
As bioinformatic prediction of miRNA targets results in high levels of false positives 
(34) a multistep process was undertaken to overcome these limitations. This 
approach resulted in approximately 150 potential gene targets of the 31 EBV 
encoded miRNAs examined. As validation of target prediction involves laborious 
assaying of post transcriptional silencing this list of potential targets needed to be 
narrowed. It was hypothesised that targeted genes may have roles in three primary 
fields; B cell differentiation pathways, immune evasion and apoptosis, so ten target 
genes with functions in these categories were selected for further analysis. 
While this study was designed to broadly identify potential new targets of EBV 
encoded miRNAs, the methodology used to accomplish this was somewhat biased. 
Only the 3‟UTR of genes was scanned for potential miRNA targets. While the 
3‟UTR is preferentially targeted by miRNAs, target sites are also found in the coding 
region of genes. More recently miRNA target sites have been predicted in the 5‟ 
UTR sequence (35). Our study did not attempt to identify targets within any of these 
regions. Targets within the coding region are more commonly targeted by a related 
family of non coding RNAs known as short interfering RNAs rather than miRNAs 
(36). These siRNAs usually bind with near perfect complementarity to the target site 
to facilitate mRNA degradation. The identification of miRNA target sites within the 
promoter and 5‟UTR regions is an extremely recent finding and was not known 
during the conception of this study and could not be incorporated. Further, most 
current miRNA target prediction programs are based upon known binding patterns to 
3‟UTR targets, which differ from miRNA binding to target sites in other regions, and 
such programs may not be able to reasonably predict such sites.  
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Table 7 Statistics of the luciferase assays of the predicted targets of BART-A miRNAs when BART-A 
or BART-B miRNAs were overexpressed. The 1
st
 column indicated the combination of reporter 
construct used in transfections. The 2
nd
 column indicates the mean of luciferase activity of the 
transfections containing the miRNA expressor as compared relative to the transfections containing 
the empty pcDNA3.1 vector, whose activity was arbitrarily defined as 1.0, with the SEM in the 2
nd
 
column (n=2). As all values for the transfections with empty pcDNA3.1 were assigned a value of 1.0 a 
one-sided T-test was performed to determine significance of the fold change with expression of the 
miRNA against the 1.0 value as indicated in the 3
rd
 column. A determination of the significance result 
as outputted by the Prism software is indicated in the 5
th
 column. 
Predicted  
BART-A Targets 
Mean Std. Error 
P value  
(two tailed) 
Significant 
 (alpha=0.05)? 
With over expression of BART-A 
 
LY75 1.009 0.06146 0.8953 No 
CTDSP2 0.9821 0.06566 0.8026 No 
MLL 0.8514 0.1542 0.4063 No 
BCL2L11 0.9152 0.06592 0.2885 No 
HIF1AN 0.9924 0.0708 0.9199 No 
BCL11A 1.144 0.1168 0.3421 No 
With over expression of BART-B 
 
LY75 0.8713 0.08436 0.2245 No 
CTDSP2 0.7888 0.08659 0.0926 No 
MLL 0.6966 0.114 0.0763 No 
BCL2L11 0.7684 0.01695 0.0008 Yes(***) 
HIF1AN 0.8911 0.1101 0.3783 No 
BCL11A 0.9637 0.1434 0.8238 No 
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Table 8 Statistics of the luciferase assays of the predicted targets of BART-B miRNAs when BART-A 
or BART-B miRNAs were overexpressed. The 1
st
 column indicated the combination of reporter 
construct used in transfections. The 2
nd
 column indicates the mean of luciferase activity of the 
transfections containing the miRNA expressor as compared relative to the transfections containing 
the empty pcDNA3.1 vector, whose activity was arbitrarily defined as 1.0, with the SEM in the 2
nd
 
column (n=2). As all values for the transfections with empty pcDNA3.1 were assigned a value of 1.0 a 
one-sided T-test was performed to determine significance of the fold change with expression of the 
miRNA against the 1.0 value as indicated in the 3
rd
 column. A determination of the significance result 
as outputted by the Prism software is indicated in the 5
th
 column. 
Predicted 
BART-B Targets 
Mean Std. Error 
P value 
(two tailed) 
Significant 
(alpha=0.05)? 
With over expression of BART-A 
 
EBF1 0.8435 0.05503 0.0654 No 
CD59a 1.104 0.1577 0.558 No 
CD59b 1.347 0.1853 0.1578 No 
HLA-DOA 0.7851 0.06671 0.0485 Yes(*) 
CD207 0.8586 0.1252 0.3758 No 
With over expression of BART-B 
 
EBF1 0.668 0.07196 0.0192 Yes(*) 
CD59a 1.065 0.1834 0.747 No 
CD59b 1.219 0.2197 0.3915 No 
HLA-DOA 0.8475 0.07023 0.1183 No 
CD207 1.51 0.5532 0.5258 No 
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While the use of a second program, TargetScan did help filter potential targets, this 
study finds that some programs may have shortcomings in specific situations, such as 
the study of viral miRNAs. TargetScan identifies potential miRNAs based upon the 
length and complementarity of the 5‟ seed region but also compares the sequence 
conservation of target sites across genomes. This option was not utilised during the 
study for a number of reasons. While some EBV encoded miRNAs have been 
evolutionarily conserved, this is only a small proportion of the entire array of EBV 
encoded miRNAs. It is not known whether EBV encoded miRNAs are generally 
conserved, nor is it known whether, conserved miRNAs target the same genes in the 
host cell. Rather, the evolutionary conservation may be due to these miRNAs 
targeting viral genes such as LMP1 or BALF5. Further, it is not known if there 
would be any evolutionary advantage for a host genome to have conserved target 
sites for viral miRNAs. As a consequence, the predictions made by TargetScan were 
not as strong as they would have been when predicting targets of endogenous 
miRNAs. Assessing the potential function of a targeted gene appears to play an 
important role in predicting miRNA targets. In comparison to a previous study which 
identified one target of EBV miRNAs out of nine potential targets, our study has 
identified three genes which are potentially targeted by EBV miRNAs out of ten 
assayed. It may be possible to improve future bioinformatic studies by utilising 
multiple predictive programs as well as predicting functional role. It is necessary 
however, to use algorithms that use different criteria to predict miRNAs.  
The current standard reporter assay used to identify potential targets of miRNA 
mediated repression is the luciferase assay. While this method is highly sensitive, it 
does have a few inherent disadvantages including the cost associated with reagents 
and time in sample processing. In order to address these disadvantages this study 
attempted to develop a new reporter system using GFP as the reporter molecule. GFP 
has previously been used as a reporter molecule in the assay of miRNA mediated 
repression,  however, it has not previously been used to identify human or viral 
miRNA targets, nor has it been used in conjunction with sophisticated cellular 
analyses such as FACS. Although time constraints did not allow the full testing of 
this system, initial data presented in Figure 4 suggested this maybe a robust, accurate 
and rapid system for miRNA target validation. 
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Luciferase reporter assays identified three targets form the ten examined which 
exhibited potential to warrant further investigation. However, despite the rigorous 
bioinformatic approach undertaken two of these targets were identified with miRNAs 
sites not identified in the bioinformatic screen illustrating the limitations of current 
algorithms. The statistical analyses that were used to analyse the luciferase assays 
may have also been a factor in identifying statistically significant down regulation. 
One sample t tests had to be used because the control was normalised to an arbitrary 
value of 1.0 and student‟s t tests could not be performed. However, this was 
necessary due to the high variation in absolute luciferase activity between assays. 
The levels of gene silencing observed in the luciferase assays was within 10% of that 
observed in the LMP1 positive control and the reduction in luciferase activity, while 
slightly less, is comparable to assays performed in other studies detecting miRNA 
targets, including other targets of EBV encoded miRNAs which predict a 30-50% in 
luciferase activity. A possible explanation for the lower level of silencing observed in 
this study may involve the structure of the EBV miRNA expressing constructs. In 
order to assay a large proportion of the EBV encoded miRNAs, the BART constructs 
we produced encoded a number of miRNAs. In contrast, other studies use either 
expression constructs for a single miRNA or precursor miRNA molecules. This may 
result in much greater expression of mature miRNA and therefore higher levels of 
repression. However, miRNAs are commonly encoded and processed as pri-
miRNAs, containing a number of miRNAs and processed primarily by Drosha. 
Particularly, pri-miRNAs can undergo RNA editing, which can change not only 
expression but also target specificity. Single miRNA expressing constructs would not 
be subject to regulation at this level while our constructs of miRNA clusters are 
likely to be regulated. Our constructs may therefore produce mature miRNA at a 
lower level but may reflect miRNAs produced in vivo more accurately. Alternatively, 
differences in experimental parameters such as transfection efficiency and reporter 
constructs may be affecting the level of reduction in luciferase activity. Particularly, 
the use of pGL3-Control as the backbone for the reporter constructs may have 
reduced the measurable effect of EBV miRNAs as pGL3-Control expresses at very 
high levels due to a strong promoter and an enhancer region, potentially saturating 
the cell with luciferase mRNA and minimising the apparent effect of EBV miRNAs. 
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This effect may be alleviated by the use of a reporter with a lower level of 
expression, such as pGL3-Promoter, which lacks the enhancer region. 
The three genes identified as lead candidates for EBV miRNA targeting provide 
potential novel insights into EBV biology within the host cell and would strongly 
impact on EBV infection and lymphomagenesis. 
HLA-DOA, a HLA class II alpha chain paralogue, is a subunit of the heterodimer 
HLA-DO, a chaperone regulating the antigen loading process of MHC class II 
molecules in the lysosomes of B cells. Dysregulation of HLA-DOA expression is 
associated with some chronic lymphocytic leukemias and its role in the presentation 
of antigen on cells may reflect a potential role in immune evasion within B cell 
malignancies. HLA-DO primarily serves to inhibit loading of peptide onto MHC 
class II molecules. While HLA-DO is expressed in both naïve and memory cells, 
HLA-DO expression in germinal centre B cells is virtually undetectable. The finding 
of potential EBV down regulation of this gene is suggestive of a possible 
involvement in the EBV-driven differentiation of infected naïve B cells paralleling 
the germinal centre reaction. 
BCL2L11 is a pro-apoptotic member of the Bcl-2 family expressed in lymphoid cells 
and is one of the major apoptotic proteins regulating the development of B 
lymphocytes. Down regulation of BCL2L11 in B cells confers resistance to apoptosis 
induced by cytokine deprivation and abnormal calcium flux. Further, BCL2L11 is a 
major component in the pathogenesis of Burkitt‟s lymphoma, which is associated 
with EBV. Down regulation of a pro-apoptotic gene such as BCL2L11 would allow 
infected B cells to evade apoptotic signals delivered to aberrant and non functional B 
cells during B cell development.  
BCL2L11, as well as other members of the Bcl-2 family, have been demonstrated to 
be targeted by EBV through the down regulation of mRNA synthesis via two EBV 
latent proteins, EBNA3A and EBNA3C, epigenetic repression of BCL2L11 
expression via methylation of the promoter region and phosphorylation of the 
protein, resulting in degradation, although subsequent studies have not observed 
down regulation of BCL2L11 via this pathway. This multifaceted approach to 
BCL2L11 regulation expression may be differentially regulated over the course of 
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EBV infection as EBNA3A and EBNA3C are expressed only during latency III, 
while BART miRNAs appear to be expressed during many latency stages.  
One of the few validated targets of EBV miRNAs is the BART5 mediated repression 
of another pro-apoptotic member of the Bcl-2 family, PUMA. Both PUMA and 
BCL2L11 are present in B cells, and play critical roles in the initiation of apoptosis. 
It is possible that EBV miRNAs may target multiple, functionally similar targets in 
order to enhance, in this case, apoptotic resistance. This has been demonstrated in 
human miRNAs clusters which target entire gene families (ref). 
EBF1 is a transcription factor that targets many B cell specific genes including B-cell 
developmental regulator Pax5. The major role of EBF1 is in the determination of 
early B cell fate, and in its absence fully functioning, mature B cells are unable to 
develop. Current studies on the role of EBF1 are focused upon the role of EBF1 in 
early B cell differentiation. However, both EBF1 and Pax5 are expressed throughout 
all stages of B cell development, with the exception of plasma cells. The role of 
EBF1 and Pax5 in the later stages of B cell development is not well understood, 
although the expression of Pax5 is necessary for the maintenance of the B cell 
phenotype. E2A is another gene, related in function to EBF1. E2A activates the 
expression of EBF1 and many of the functional effects of E2A are caused by the 
regulation of EBF1. E2A has been demonstrated to be necessary in germinal centre 
development and can induce apoptosis within primary effusion lymphoma lines. 
EBV may regulate EBF1 expression to aid in the exploitation of B cell differentiation 
pathways and potentially, confer a level of apoptotic resistance. 
EBF1 and Pax5 are activated by the stimulation of CD40, a B cell surface receptor. 
CD40 interacts with the T cell receptor CD154 and this process is essential in the 
stimulation of antigen and T cell dependent B cell proliferation. EBV expresses a 
constitutively active homologue of CD40, LMP-1, allowing infected cells to undergo 
T cell independent proliferation and be driven through the germinal centre reaction in 
the absence of external signals. It is possible that LMP1 may also activate EBF1 and 
the down regulation of EBF1 via miRNA mediated repression may have an 
attenuating effect on this activation. While this highlights a potential link between 
EBV and EBF1, it is not clear what functional role this could have. 
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This study has identified three novel, putative targets of EBV encoded miRNAs 
through miRNA mediated down regulation observed in luciferase reporter gene 
experiments. These observations need to be further confirmed using more 
physiological relevant methods such as Western blotting demonstration of down 
regulation of targeted proteins within EBV infected cells. Further, while potential 
target sites within the 3‟ UTRs have been identified for EBF1 and BCL2L11, target 
sites have not been predicted for HLA-DOA. Neither have target sites been 
confirmed nor the miRNAs responsible for down regulation of HLA-DOA, 
BCL2L11 and EBF1 confirmed. These questions could be addressed using site 
directed mutagenesis of the predicted miRNA binding sites in the luciferase reporter 
constructs, and experiments with individual EBV miRNAs. In addition functional 
roles of HLA-DOA, BCL2L11 and EBF1 down regulation in EBV pathogenesis 
need to be identified. For example, apoptotic assays were used to demonstrate the 
functional role of BART5 repression of PUMA in protecting cells against apoptosis. 
Particularly, the function of HLA-DOA and EBF1 in EBV pathogenesis needs to be 
identified, as potential roles for these genes is less clear than for BCL2L11. Further 
study into the potential effect of EBV encoded miRNAs on genes related to these 
targets is also warranted, as the targeting of both PUMA and BCL2L11 by EBV 
encoded miRNAs suggests that functionally similar genes may also be targeted. 
The role EBV encoded miRNAs play in infected cells and their contribution to EBV 
associated malignancies such as Burkitt‟s and Hodgkin‟s lymphoma is currently not 
well understood. While studies identifying differential expression of EBV miRNAs 
between normal and malignant cells suggest that they do play a part, it is necessary 
to identify the targets of EBV miRNAs in order to assess the role they are playing. 
This study has identified three potential targets of EBV encoded miRNAs within the 
human genome and following studies will confirm and elucidate the targeting of 
these genes. Understanding the potential role these genes play in the development 
and persistence of B cell malignancies will elucidate the relationship between EBV 
and lymphoma. 
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